Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)

ABSTRACT

The invention provides a human FPRL1 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD, asthma, genito-urological disorders and inflammation diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD, asthma, genito-urological disorders and inflammation diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of FPRL1 as well as pharmaceutical compositions comprising such compounds.

TECHNICAL FIELD OF THE INVENTION

The present invention is in the field of molecular biology, moreparticularly, the present invention relates to nucleic acid sequencesand amino acid sequences of a human FPRL1 and its regulation for thetreatment of hematological diseases, cardiovascular diseases, disordersof the peripheral and central nervous system, respiratory diseases likeCOPD, asthma, genito-urological disorders and inflammation diseases inmammals.

BACKGROUND OF THE INVENTION

G-Protein Coupled Receptors

FPRL1 is a seven transmembrane G protein coupled receptor (GPCR) [Murphyet al. (1992), Durstin et al. (1994), WO 01/77172]. Many medicallysignificant biological processes are mediated by signal transductionpathways that involve G-proteins [Lefkowitz, (1991)]. The family ofG-protein coupled receptors (GPCRs) includes receptors for hormones,neurotransmitters, growth factors, and viruses. Specific examples ofGPCRs include receptors for such diverse agents as dopamine,calcitonine, adrenergic hormones, endotheline, cAMP, adenosine,acetylcholine, serotonine, histamine, thrombin, kinine, folliclestimulating hormone, opsins, endothelial differentiation gene-1,rhodopsins, odorants, cytomegalovirus, G-proteins themselves, effectorproteins such as phospholipase C, adenyl cyclase, and phosphodiesterase,and actuator proteins such as protein kinase A and protein kinase C.

GPCRs possess seven conserved membrane-spannig domains connecting atleast eight divergent hydrophilic loops. GPCRs, also known as seventransmembrane, 7TM, receptors, have been characterized as includingthese seven conserved hydrophobic stretches of about 20 to 30 aminoacids, connecting at least eight divergent hydrophilic loops. Most GPCRshave single conserved cysteine residues in each of the first twoextracellular loops, which form disulfide bonds that are believed tostabilize functional protein structure. The seven transmembrane regionsare designated as TM1, TM2, TM3, TM4, TM5, TM6, and TM7. TM3 is beingimplicated with signal transduction. Phosphorylation and lipidation(pahlitylation or farnesylation) of cysteine residues can influencesignal transduction of some GPCRs. Most GPCRs contain potentialphosphorylation sites within the third cytoplasmic loop and/or thecarboxy terminus. For several GPCRs, such as the beta-adrenergicreceptor, phosphorylation by protein kinase A and/or specific receptorkinases mediates receptor desensitization.

For some receptors, the ligand binding sites of GPCRs are believed tocomprise hydrophilic sockets formed by several GPCR transmembranedomains. The hydrophilic sockets are surrounded by hydrophobic residuesof the GPCRs. The hydrophilic side of each GPCR transmembrane helix ispostulated to face inward and form a polar ligand binding site. TM3 isbeing implicated with several GPCRs as having a ligand binding site,such as the TM3 aspartate residue. TM5 serines, a TM6 asparagine, andTM6 or TM7 phenylalanines or tyrosines also are implicated in ligandbinding.

GPCRs are coup led inside the cell by heterotrimeric G-proteins tovarious intra-cellular enzymes, ion channels, and transporters.Different G-protein alpha-subunits preferentially stimulate particulareffectors to modulate various biological functions in a cell.Phosphorylation of cytoplasmic residues of GPCRs is an importantmechanism for the regulation of some GPCRs. For example, in one form ofsignal transduction, the effect of hormone binding is the activation ofthe enzyme, adenylate cyclase, inside the cell. Enzyme activation byhormones is dependent on the presence of the nucleotide GTP. GTP alsoinfluences hormone binding. A G-protein connects the hormone receptor toadenylate cyclase. G-protein exchanges GTP for bound GDP when activatedby a hormone receptor. The GTP-carrying form then binds to activatedadenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-proteinitself, returns the G-protein to its basal, inactive form. Thus, theG-protein serves a dual role, as an intermediate that relays the signalfrom receptor to effector, and as a clock that controls the duration ofthe signal.

Over the past 15 years, nearly 350 therapeutic agents targeting 7TMreceptors have been successfully introduced into the market. Thisindicates that these receptors have an established, proven history astherapeutic targets. Clearly, there is a need for identification andcharacterization of further receptors which can play a role inpreventing, ameliorating, or correcting dysfunctions or diseasesincluding, but not limited to, infections such as bacterial, fungal,protozoan, and viral infections, particularly those caused by HIVviruses, cancers, allergies including asthma, cardiovascular diseasesincluding acute heart failure, hypotension, hypertension, anginapectoris, myocardial infarction, haematological diseases, genito-urinarydiseases including urinary incontinence and benign prostate hyperplasia,osteoporosis, and peripheral and central nervous system disordersincluding pain, Alzheimer's disease and Parkinson's disease.

TaqMan-Technology/Expression Profiling

TaqMan is a recently developed technique, in which the release of afluorescent reporter dye from a hybridisation probe in real-time duringa polymerase chain reaction (PCR) is proportional to the accumulation ofthe PCR product. Quantification is based on the early, linear part ofthe reaction, and by determining the threshold cycle (CT), at whichfluorescence above background is first detected.

Gene expression technologies may be useful in several areas of drugdiscovery and development, such as target identification, leadoptimization, and identification of mechanisms of action. The TaqMantechnology can be used to compare differences between expressionprofiles of normal tissue and diseased tissue. Expression profiling hasbeen used in identifying genes, which are up- or downregulated in avariety of diseases. An interesting application of expression profilingis temporal monitoring of changes in gene expression during diseaseprogression and drug treatment or in patients versus healthyindividuals. The premise in this approach is that changes in pattern ofgene expression in response to physiological or environmental stimuli(e.g., drugs) may serve as indirect clues about disease-causing genes ordrug targets. Moreover, the effects of drugs with established efficacyon global gene expression patterns may provide a guidepost, or a geneticsignature, against which a new drug candidate can be compared.

FPRL1

The nucleotide sequence of FPRL1 is accessible in public databases bythe accession number NM_(—)001462 and is given in SEQ ID NO:1. The aminoacid sequence of FPRL1 is depicted in SEQ ID NO:2. FPRL1 is described asa receptor for N-formyl-peptides. The expression of the receptor inphagocytes and neutrophils was described before. The receptor FPRL1shows the highest homology to N-formyl peptide receptor from G.gorilla(X97738).

SUMMARY OF THE INVENTION

The invention relates to novel disease associations of FPRL1polypeptides and polynucleotides. The invention also relates to novelmethods of screening for therapeutic agents for the treatment ofhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases like COPD,asthma, genito-urological disorders and inflammation diseases in amammal. The invention also relates to pharmaceutical compositions forthe treatment of hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases like COPD, asthma, genito-urological disorders and inflammationdiseases in a mammal comprising a FPRL1 polypeptide, a FPRL1polynucleotide, or regulators of FPRL1 or modulators of FPRL1 activity.

The invention further comprises methods of diagnosing hematologicaldiseases, cardiovascular diseases, disorders of the peripheral andcentral nervous system, respiratory diseases like COPD, asthma,genito-urological disorders and inflammation diseases in a mammal.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the nucleotide sequence of a FPRL1 receptor polynucleotide(SEQ ID NO:1).

FIG. 2 shows the amino acid sequence of a FPRL1 receptor polypeptide(SEQ ID NO:2).

FIG. 3 shows the nucleotide sequence of a primer useful for theinvention (SEQ ID NO:3).

FIG. 4 shows the nucleotide sequence of a primer useful for theinvention (SEQ ID NO:4).

FIG. 5 shows a nucleotide sequence useful as a probe to detect proteinsof the invention (SEQ ID NO:5).

DETAILED DESCRIPTION OF THE INVENTION

Definition of Terms

An “oligonucleotide” is a stretch of nucleotide residues which has asufficient number of bases to be used as an oligomer, amplimer or probein a polymerase chain reaction (PCR). Oligonucleotides are prepared fromgenomic or cDNA sequence and are used to amplify, reveal, or confirm thepresence of a similar DNA or RNA in a particular cell or tissue.Oligonucleotides or oligomers comprise portions of a DNA sequence havingat least about 10 nucleotides and as many as about 35 nucleotides,preferably about 25 nucleotides.

“Probes” may be derived from naturally occurring or recombinant single-or double-stranded nucleic acids or may be chemically synthesized. Theyare useful in detecting the presence of identical or similar sequences.Such probes may be labeled with reporter molecules using nicktranslation, Klenow fill-in reaction, PCR or other methods well known inthe art. Nucleic acid probes may be used in southern, northern or insitu hybridizations to determine whether DNA or RNA encoding a certainprotein is present in a cell type, tissue, or organ.

A “fragment of a polynucleotide” is a nucleic acid that comprises all orany part of a given nucleotide molecule, the fragment having fewernucleotides than about 6 kb, preferably fewer than about 1 kb.

“Reporter molecules” are radionuclides, enzymes, fluorescent,chemiluminescent, or chromogenic agents which associate with aparticular nucleotide or amino acid sequence, thereby establishing thepresence of a certain sequence, or allowing for the quantification of acertain sequence.

“Chimeric” molecules may be constructed by introducing all or part ofthe nucleotide sequence of this invention into a vector containingadditional nucleic acid sequence which might be expected to change anyone or several of the following FPRL1 characteristics: cellularlocation, distribution, ligand-binding affinities, interchainaffinities, degradation/turnover rate, signaling, etc.

“Active”, with respect to a FPRL1 polypeptide, refers to those forms,fragments, or domains of a FPRL1 polypeptide which retain the biologicaland/or antig-enic activity of a FPRL1 polypeptide.

“Naturally occurring FPRL1 polypeptide” refers to a polypeptide producedby cells which have not been genetically engineered and specificallycontemplates various polypeptides arising from post-translationalmodifications of the polypeptide including but not limited toacetylation, carboxylation, glycosylation, phosphorylation, lipidationand acylation.

“Derivative” refers to polypeptides which have been chemically modifiedby techniques such as ubiquitination, labeling (see above), pegylation(derivatization with polyethylene glycol), and chemical insertion orsubstitution of amino acids such as ornithine which do not normallyoccur in human proteins.

“Conservative amino acid substitutions” result from replacing one aminoacid with another having similar structural and/or chemical properties,such as the replacement of a leucine with an isoleucine or valine, anaspartate with a glutamate, or a threonine with a serine.

“Insertions” or “deletions” are typically in the range of about 1 to 5amino acids. The variation allowed may be experimentally determined byproducing the peptide synthetically while systematically makinginsertions, deletions, or substitutions of nucleotides in the sequenceusing recombinant DNA techniques.

A “signal sequence” or “leader sequence” can be used, when desired, todirect the polypeptide through a membrane of a cell. Such a sequence maybe naturally present on the polypeptides of the present invention orprovided from heterologous sources by recombinant DNA techniques.

An “oligopeptide” is a short stretch of amino acid residues and may beexpressed from an oligonucleotide. Oligopeptides comprise a stretch ofamino acid residues of at least 3, 5, 10 amino acids and at most 10, 15,25 amino acids, typically of at least 9 to 13 amino acids, and ofsufficient length to display biological and/or antigenic activity.

“Inhibitor” is any substance which retards or prevents a chemical orphysiological reaction or response. Common inhibitors include but arenot limited to antisense molecules, antibodies, and antagonists.

“Standard expression” is a quantitative or qualitative measurement forcomparison It is based on a statistically appropriate number of normalsamples and is created to use as a basis of comparison when performingdiagnostic assays, running clinical trials, or following patienttreatment profiles.

“Animal” as used herein may be defined to include human, domestic (e.g.,cats, dogs, etc.), agricultural (e.g., cows, horses, sheep, etc.) ortest species (e.g., mouse, rat, rabbit, etc.).

A “FPRL1 polynucleotide”, within the meaning of the invention, shall beunderstood as being a nucleic acid molecule selected from a groupconsisting of

-   (i) nucleic acid molecules encoding a polypeptide comprising the    amino acid sequence of SEQ ID NO: 2,-   (ii) nucleic acid molecules comprising the sequence of SEQ ID NO: 1,-   (iii) nucleic acid molecules having the sequence of SEQ ID NO: 1,-   (iv) nucleic acid molecules the complementary strand of which    hybridizes under stringent conditions to a nucleic acid molecule of    (i), (ii), or (iii); and-   (v) nucleic acid molecules the sequence of which differs from the    sequence of a nucleic acid molecule of (iii) due to the degeneracy    of the genetic code;    wherein the polypeptide encoded by said nucleic acid molecule has    FPRL1 activity.

A “FPRL1 polypeptide”, within the meaning of the invention, shall beunderstood as being a polypeptide selected from a group consisting of

-   (i) polypeptides having the sequence of SEQ ID NO: 2,-   (ii) polypeptides comprising the sequence of SEQ ID NO: 2,-   (iii) polypeptides encoded by FPRL1 polynucleotides; and-   (iv) polypeptides which show at least 99%, 98%, 95%, 90%, or 80%    homology with a polypeptide of (i), (ii), or (iii);    wherein said polypeptide has FPRL1 activity.

The nucleotide sequences encoding a FPRL1 (or their complement) havenumerous applications in techniques known to those skilled in the art ofmolecular biology. These techniques include use as hybridization probes,use in the construction of oligomers for PCR, use for chromosome andgene mapping, use in the recombinant production of FPRL1, and use ingeneration of antisense DNA or RNA, their chemical analogs and the like.Uses of nucleotides encoding a FPRL1 disclosed herein are exemplary ofknown techniques and are not intended to limit their use in anytechnique known to a person of ordinary skill in the art. Furthermore,the nucleotide sequences disclosed herein may be used in molecularbiology techniques that have not yet been developed, provided the newtechniques rely on properties of nucleotide sequences that are currentlyknown, e.g., the triplet genetic code, specific base pair interactions,etc.

It will be appreciated by those skilled in the art that as a result ofthe degeneracy of the genetic code, a multitude of FPRL1-encodingnucleotide sequences may be produced. Some of these will only bearminimal homology to the nucleotide sequence of the known and naturallyoccurring FPRL1. The invention has specifically contemplated each andevery possible variation of nucleotide sequence that could be made byselecting combinations based on possible codon choices. Thesecombinations are made in accordance with the standard triplet geneticcode as applied to the nucleotide sequence of naturally occurring FPRL1,and all such variations are to be considered as being specificallydisclosed.

Although the nucleotide sequences which encode a FPRL1, its derivativesor its variants are preferably capable of hybridizing to the nucleotidesequence of the naturally occurring FPRL1 polynucleotide under stringentconditions, it may be advantageous to produce nucleotide sequencesencoding FPRL1 polypeptides or its derivatives possessing asubstantially different codon usage. Codons can be selected to increasethe rate at which expression of the peptide occurs in a particularprokaryotic or eukaryotic expression host in accordance with thefrequency with which particular codons are utilized by the host. Otherreasons for substantially altering the nucleotide sequence encoding aFPRL1 polypeptide and/or its derivatives without altering the encodedamino acid sequence include the production of RNA transcripts havingmore desirable properties, such as a greater half-life, than transcriptsproduced from the naturally occurring sequence.

Nucleotide sequences encoding a FPRL1 polypeptide may be joined to avariety of other nucleotide sequences by means of well establishedrecombinant DNA techniques. Useful nucleotide sequences for joining toFPRL1 polynucleotides include an assortment of cloning vectors such asplasmids, cosmids, lambda phage derivatives, phagemids, and the like.Vectors of interest include expression vectors, replication vectors,probe generation vectors, sequencing vectors, etc. In general, vectorsof interest may contain an origin of replication functional in at leastone organism, convenient restriction endonuclease sensitive sites, andselectable markers for one or more host cell systems.

Another aspect of the subject invention is to provide for FPRL1-specifichybridization probes capable of hybridizing with naturally occurringnucleotide sequences encoding FPRL1. Such probes may also be used forthe detection of similar GPCR encoding sequences and should preferablyshow at least 40% nucleotide identity to FPRL1 polynucleotides. Thehybridization probes of the subject invention may be derived from thenucleotide sequence presented as SEQ ID NO: 1 or from genomic sequencesincluding promoter, enhancers or introns of the native gene.Hybridization probes may be labelled by a variety of reporter moleculesusing techniques well known in the art.

It will be recognized that many deletional or mutational analogs ofFPRL1 poly-nucleotides will be effective hybridization probes for FPRL1polynucleotides. Accordingly, the invention relates to nucleic acidsequences that hybridize with such FPRL1 encoding nucleic acid sequencesunder stringent conditions.

“Stringent conditions” refers to conditions that allow for thehybridization of substantially related nucleic acid sequences. Forinstance, such conditions will generally allow hybridization of sequencewith at least about 85% sequence identity, preferably with at leastabout 90% sequence identity, more preferably with at least about 95%sequence identity. Hybridization conditions and probes can be adjustedin well-characterized ways to achieve selective hybridization ofhuman-derived probes. Stringent conditions, within the meaning of theinvention are 65° C. in a buffer containing 1 mM EDTA, 0.5 M NaHPO₄ (pH7.2), 7% (w/v) SDS.

Nucleic acid molecules that will hybridize to FPRL1 polynucleotidesunder stringent conditions can be identified functionally. Withoutlimitation, examples of the uses for hybridization probes include:histochemical uses such as identifying tissues that express FPRL1;measuring mRNA levels, for instance to identify a sample's tissue typeor to identify cells that express abnormal levels of FPRL1; anddetecting poly-morphisms of FPRL1.

PCR provides additional uses for oligonucleotides based upon thenucleotide sequence which encodes FPRL1. Such probes used in PCR may beof recombinant origin, chemically synthesized, or a mixture of both.Oligomers may comprise discrete nucleotide sequences employed underoptimized conditions for identification of FPRL1 in specific tissues ordiagnostic use. The same two oligomers, a nested set of oligomers, oreven a degenerate pool of oligomers may be employed under less stringentconditions for identification of closely related DNAs or RNAs.

Rules for designing polymerase chain reaction (PCR) primers are nowestablished, as reviewed by PCR Protocols. Degenerate primers, i.e.,preparations of primers that are heterogeneous at given sequencelocations, can be designed to amplify nucleic acid sequences that arehighly homologous to, but not identical with FPRL1. Strategies are nowavailable that allow for only one of the primers to be required tospecifically hybridize with a known sequence. For example, appropriatenucleic acid primers can be ligated to the nucleic acid sought to beamplified to provide the hybridization partner for one of the primers.In this way, only one of the primers need be based on the sequence ofthe nucleic acid sought to be amplified.

PCR methods for amplifying nucleic acid will utilize at least twoprimers. One of these primers will be capable of hybridizing to a firststrand of the nucleic acid to be amplified and of priming enzyme-drivennucleic acid synthesis in a first direction. The other will be capableof hybridizing the reciprocal sequence of the first strand (if thesequence to be amplified is single stranded, this sequence willinitially be hypothetical, but will be synthesized in the firstamplification cycle) and of priming nucleic acid synthesis from thatstrand in the direction opposite the first direction and towards thesite of hybridization for the first primer. Conditions for conductingsuch amplifications, particularly under preferred stringenthybridization conditions, are well known.

Other means of producing specific hybridization probes for FPRL1 includethe cloning of nucleic acid sequences encoding FPRL1 or FPRL1derivatives into vectors for the production of mRNA probes. Such vectorsare known in the art, are commercially available and may be used tosynthesize RNA probes in vitro by means of the addition of theappropriate RNA polymerase as T7 or SP6 RNA polymerase and theappropriate reporter molecules.

It is possible to produce a DNA sequence, or portions thereof, entirelyby synthetic chemistry. After synthesis, the nucleic acid sequence canbe inserted into any of the many available DNA vectors and theirrespective host cells using techniques which are well known in the art.Moreover, synthetic chemistry may be used to introduce mutations intothe nucleotide sequence. Alternately, a portion of sequence in which amutation is desired can be synthesized and recombined with longerportion of an existing genomic or recombinant sequence.

FPRL1 polynucleotides may be used to produce a purified oligo- orpolypeptide using well known methods of recombinant DNA technology. Theoligopeptide may be expressed in a variety of host cells, eitherprokaryotic or eukaryotic. Host cells may be from the same species fromwhich the nucleotide sequence was derived or from a different species.Advantages of producing an oligonucleotide by recombinant DNA technologyinclude obtaining adequate amounts of the protein for purification andthe availability of simplified purification procedures.

Quantitative Determinations of Nucleic Acids

An important step in the molecular genetic analysis of human disease isoften the enumeration of the copy number of a nucleis acid or therelative expression of a gene in particular tissues.

Several different approaches are currently available to makequantitative determinations of nucleic acids. Chromosome-basedtechniques, such as comparative genomic hybridization (CGH) andfluorescent in situ hybridization (FISH) facilitate efforts tocytogenetically localize genomic regions that are altered in tumorcells. Regions of genomic alteration can be narrowed further using lossof heterozygosity analysis (LOH), in which disease DNA is analyzed andcompared with normal DNA for the loss of a heterozygous polymorphicmarker. The first experiments used restriction fragment lengthpolymorphisms (RFLPs) [Johnson, (1989)], or hyper-variable minisatelliteDNA [Barnes, 2000]. In recent years LOH has been performed primarilyusing PCR amplification of microsatellite markers and electrophoresis ofthe radio labelled [Jeffreys, (1985)] or fluorescently labelled PCRproducts [Weber, (1990)] and compared between paired normal and diseaseDNAs.

A number of other methods have also been developed to quantify nucleicacids [Gergen, (1992)]. More recently, PCR and RT-PCR methods have beendeveloped which are capable of measuring the amount of a nucleic acid ina sample. One approach, for example, measures PCR product quantity inthe log phase of the reaction before the formation of reaction productsplateaus [Thomas, (1980)].

A gene sequence contained in all samples at relatively constant quantityis typically utilized for sample amplification efficiency normalization.This approach, however, suffers from several drawbacks. The methodrequires that each sample has equal input amounts of the nucleic acidand that the amplification efficiency between samples is identical untilthe time of analysis. Furthermore, it is difficult using theconventional methods of PCR quantitation such as gel electrophoresis orplate capture hybridization to determine that all samples are in factanalyzed during the log phase of the reaction as required by the method.

Another method called quantitative competitive (QC)-PCR, as the nameimplies, relies on the inclusion of an internal control competitor ineach reaction [Piatak, (1993), BioTechniques]. The efficiency of eachreaction is normalized to the internal competitor. A known amount ofinternal competitor is typically added to each sample. The unknowntarget PCR product is compared with the known competitor PCR product toobtain relative quantitation. A difficulty with this general approachlies in developing an internal control that amplifies with the sameefficiency than the target molecule.

5′Fluorogenic Nuclease Assays

Fluorogenic nuclease assays are a real time quantitation method thatuses a probe to monitor formation of amplification product. The basisfor this method of monitoring the formation of amplification product isto measure continuously PCR product accumulation using a dual-labelledfluorogenic oligonucleotide probe, an approach frequently referred to inthe literature simply as the “TaqMan method” [Piatak, (1993), Science;Heid, (1996); Gibson, (1996); Holland. (1991)].

The probe used in such assays is typically a short (about 20-25 bases)oligonucleotide that is labeled with two different fluorescent dyes. The5′ terminus of the probe is attached to a reporter dye and the 3′terminus is attached to a quenching dye, although the dyes could beattached at other locations on the probe as well. The probe is designedto have at least substantial sequence complementarity with the probebinding site. Upstream and downstream PCR primers which bind to flankingregions of the locus are added to the reaction mixture. When the probeis intact, energy transfer between the two fluorophors occurs and thequencher quenches emission from the reporter. During the extension phaseof PCR, the probe is cleaved by the 5′ nuclease activity of a nucleicacid polymerase such as Taq polymerase, thereby releasing the reporterfrom the oligonucleotide-quencher and resulting in an increase ofreporter emission intensity which can be measured by an appropriatedetector.

One detector which is specifically adapted for measuring fluorescenceemissions such as those created during a fluorogenic assay is the ABI7700 or 4700 HT manufactured by Applied Biosystems, Inc. in Foster City,Calif. The ABI 7700 uses fiber optics connected with each well in a 96-or 384 well PCR tube arrangement. The instrument includes a laser forexciting the labels and is capable of measuring the fluorescence spectraintensity from each tube with continuous monitoring during PCRamplification. Each tube is re-examined every 8.5 seconds.

Computer software provided with the instrument is capable of recordingthe fluorescence intensity of reporter and quencher over the course ofthe amplification. The recorded values will then be used to calculatethe increase in normalized reporter emission intensity on a continuousbasis. The increase in emission intensity is plotted versus time, i.e.,the number of amplification cycles, to produce a continuous measure ofamplification. To quantify the locus in each amplification reaction, theamplification plot is examined at a point during the log phase ofproduct accumulation. This is accomplished by assigning a fluorescencethreshold intensity above background and determining the point at whicheach amplification plot crosses the threshold (defined as the thresholdcycle number or Ct). Differences in threshold cycle number are used toquantify the relative amount of PCR target contained within each tube.Assuming that each reaction functions at 100% PCR efficiency, adifference of one Ct represents a two-fold difference in the amount ofstarting template. The fluorescence value can be used in conjunctionwith a standard curve to determine the amount of amplification productpresent.

Non-Probe-Based Detection Methods

A variety of options are available for measuring the amplificationproducts as they are formed. One method utilizes labels, such as dyes,which only bind to double stranded DNA. In this type of approach,amplification product (which is double stranded) binds dye molecules insolution to form a complex. With the appropriate dyes, it is possible todistinguish between dye molecules free in solution and dye moleculesbound to amplification product. For example, certain dyes fluoresce onlywhen bound to amplification product. Examples of dyes which can be usedin methods of this general type include, but are not limited to, SyberGreen™ and Pico Green from Molecular Probes, Inc. of Eugene, Oreg.,ethidium bromide, propidium iodide, chromomycin, acridine orange,Hoechst 33258, Toto-1, Yoyo-1, DAPI (4′,6-diamidino-2-phenylindolehydrochloride).

Another real time detection technique measures alteration in energyfluorescence energy transfer between fluorophors conjugated with PCRprimers [Livak, (1995)].

Probe-Based Detection Methods

These detection methods involve some alteration to the structure orconformation of a probe hybridized to the locus between theamplification primer pair. In some instances, the alteration is causedby the template-dependent extension catalyzed by a nucleic acidpolymerase during the amplification process. The alteration generates adetectable signal which is an indirect measure of the amount ofamplification product formed.

For example, some methods involve the degradation or digestion of theprobe during the extension reaction. These methods are a consequence ofthe 5′-3′ nuclease activity associated with some nucleic acidpolymerases. Polymerases having this activity cleave mononucleotides orsmall oligonucleotides from an oligonucleotide probe annealed to itscomplementary sequence located within the locus.

The 3′ end of the upstream primer provides the initial binding site forthe nucleic acid polymerase. As the polymerase catalyzes extension ofthe upstream primer and encounters the bound probe, the nucleic acidpolymerase displaces a portion of the 5′ end of the probe and throughits nuclease activity cleaves mononucleotides or oligo-nucleotides fromthe probe.

The upstream primer and the probe can be designed such that they annealto the complementary strand in close proximity to one another. In fact,the 3′ end of the upstream primer and the 5′ end of the probe may abutone another. In this situation, extension of the upstream primer is notnecessary in order for the nucleic acid polymerase to begin cleaving theprobe. In the case in which intervening nucleotides separate theupstream primer and the probe, extension of the primer is necessarybefore the nucleic acid polymerase encounters the 5′ end of the probe.Once contact occurs and polymerization continues, the 5′-3′ exonucleaseactivity of the nucleic acid polymerase begins cleaving mononucleotidesor oligonucleotides from the 5′ end of the probe. Digestion of the probecontinues until the remaining portion of the probe dissociates from thecomplementary strand.

In solution, the two end sections can hybridize with each other to forma hairpin loop. In this conformation, the reporter and quencher dye arein sufficiently close proximity that fluorescence from the reporter dyeis effectively quenched by the quencher dye. Hybridized probe, incontrast, results in a linearized conformation in which the extent ofquenching is decreased. Thus, by monitoring emission changes for the twodyes, it is possible to indirectly monitor the formation ofamplification product.

Probes

The labeled probe is selected so that its sequence is substantiallycomplementary to a segment of the test locus or a reference locus. Asindicated above, the nucleic acid site to which the probe binds shouldbe located between the primer binding sites for the upstream anddownstream amplification primers.

Primers

The primers used in the amplification are selected so as to be capableof hybridizing to sequences at flanking regions of the locus beingamplified. The primers are chosen to have at least substantialcomplementarity with the different strands of the nucleic acid beingamplified. When a probe is utilized to detect the formation ofamplification products, the primers are selected in such that they flankthe probe, i.e. are located upstream and downstream of the probe.

The primer must have sufficient length so that it is capable of primingthe synthesis of extension products in the presence of an agent forpolymerization. The length and composition of the primer depends on manyparameters, including, for example, the temperature at which theannealing reaction is conducted, proximity of the probe binding site tothat of the primer, relative concentrations of the primer and probe andthe particular nucleic acid composition of the probe. Typically theprimer includes 15-30 nucleotides. However, the length of the primer maybe more or less depending on the complexity of the primer binding siteand the factors listed above.

Labels for Probes and Primers

The labels used for labeling the probes or primers of the currentinvention and which can provide the signal corresponding to the quantityof amplification product can take a variety of forms. As indicated abovewith regard to the 5′ fluorogenic nuclease method, a fluorescent signalis one signal which can be measured. However, measurements may also bemade, for example, by monitoring radioactivity, colorimetry, absorption,magnetic parameters, or enzymatic activity. Thus, labels which can beemployed include, but are not limited to, fluorophors, chromophores,radioactive isotopes, electron dense reagents, enzymes, and ligandshaving specific binding partners (e.g., biotin-avidin).

Monitoring changes in fluorescence is a particularly useful way tomonitor the accumulation of amplification products. A number of labelsuseful for attachment to probes or primers are commercially availableincluding fluorescein and various fluorescein derivatives such as FAM,HEX, TET and JOE (all which are available from Applied Biosystems,Foster City, Calif.); lucifer yellow, and coumarin derivatives.

Labels may be attached to the probe or primer using a variety oftechniques and can be attached at the 5′ end, and/or the 3′ end and/orat an internal nucleotide. The label can also be attached to spacer armsof various sizes which are attached to the probe or primer. These spacerarms are useful for obtaining a desired distance between multiple labelsattached to the probe or primer.

In some instances, a single label may be utilized; whereas, in otherinstances, such as with the 5′ fluorogenic nuclease assays for example,two or more labels are attached to the probe. In cases wherein the probeincludes multiple labels, it is generally advisable to maintain spacingbetween the labels which is sufficient to permit separation of thelabels during digestion of the probe through the 5′-3′ nuclease activityof the nucleic acid polymerase.

Patients Exhibiting Symptoms of Disease

A number of diseases are associated with changes in the copy number of acertain gene. For patients having symptoms of a disease, the real-timePCR method can be used to determine if the patient has copy numberalterations which are known to be linked with diseases that areassociated with the symptoms the patient has.

FPRL1 Expression

FPRL1 Fusion Proteins

Fusion proteins are useful for generating antibodies against FPRL1polypeptides and for use in various assay systems. For example, fusionproteins can be used to identify proteins which interact with portionsof FPRL1 polypeptides. Protein affinity chromatography or library-basedassays for protein-protein interactions, such as the yeast two-hybrid orphage display systems, can be used for this purpose. Such methods arewell known in the art and also can be used as drug screens.

A FPRL1 fusion protein comprises two polypeptide segments fused togetherby means of a peptide bond. The first polypeptide segment can compriseat least 54, 75, 100, 125, 139, 150, 175, 200, 225, 250, or 275contiguous amino acids of SEQ ID NO: 2 or of a biologically activevariant, such as those described above. The first polypeptide segmentalso can comprise full-length FPRL1.

The second polypeptide segment can be a full-length protein or a proteinfragment. Proteins commonly used in fusion protein construction include,but are not limited to β galactosidase, β-glucuronidase, greenfluorescent protein (GFP), autofluorescent proteins, including bluefluorescent protein (BFP), glutathione-S-transferase (GST), luciferase,horseradish peroxidase (IRP), and chloramphenicol acetyltransferase(CAT). Additionally, epitope tags are used in fusion proteinconstructions, including histidine (His) tags, FLAG tags, influenzahemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx)tags. Other fusion constructions can include maltose binding protein(MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA bindingdomain fusions, herpes simplex virus (HSV) BP16 protein fusions andG-protein fusions (for example G(alpha)16, Gs, Gi). A fusion proteinalso can be engineered to contain a cleavage site located adjacent tothe FPRL1.

Preparation of Polynucleotides

A naturally occurring FPRL1 polynucleotide can be isolated free of othercellular components such as membrane components, proteins, and lipids.Polynucleotides can be made by a cell and isolated using standardnucleic acid purification techniques, or synthesized using anamplification technique, such as the polymerase chain reaction (PCR), orby using an automatic synthesizer. Methods for isolating polynucleotidesare routine and are known in the art. Any such technique for obtaining apolynucleotide can be used to obtain isolated FPRL1 polynucleotides. Forexample, restriction enzymes and probes can be used to isolatepolynucleotide fragments which comprise FPRL-1 nucleotide sequences.Isolated polynucleotides are in preparations which are free or at least70, 80, or 90% free of other molecules.

FPRL1 cDNA molecules can be made with standard molecular biologytechniques, using FPRL1 mRNA as a template. FPRL1 cDNA molecules canthereafter be replicated using molecular biology techniques known in theart. An amplification technique, such as PCR, can be used to obtainadditional copies of polynucleotides of the invention, using eitherhuman genomic DNA or cDNA as a template.

Alternatively, synthetic chemistry techniques can be used to synthesizesFPRL1 polynucleotides. The degeneracy of the genetic code allowsalternate nucleotide sequences to be synthesized which will encode FPRL1having, for example, an amino acid sequence shown in SEQ ID NO: 2 or abiologically active variant thereof.

Extending Polynucleotides

Various PCR-based methods can be used to extend nucleic acid sequencesencoding human FPRL1, for example to detect upstream sequences of FPRL1gene such as promoters and regulatory elements. For example,restriction-site PCR uses universal primers to retrieve unknown sequenceadjacent to a known locus. Genomic DNA is first amplified in thepresence of a primer to a linker sequence and a primer specific to theknown region. The amplified sequences are then subjected to a secondround of PCR with the same linker primer and another specific primerinternal to the first one. Products of each round of PCR are transcribedwith an appropriate RNA polymerase and sequenced using reversetranscriptase.

Inverse PCR also can be used to amplify or extend sequences usingdivergent primers based on a known region. Primers can be designed usingcommercially available software, such as OLIGO 4.06 Primer Analysissoftware (National Biosciences Inc., Plymouth, Minn.), to be 22-30nucleotides in length, to have a GC content of 50% or more, and toanneal to the target sequence at temperatures about 68-72° C. The methoduses several restriction enzymes to generate a suitable fragment in theknown region of a gene. The fragment is then circularized byintramolecular ligation and used as a PCR template.

Another method which can be used is capture PCR, which involves PCRamplification of DNA fragments adjacent to a known sequence in human andyeast artificial chromosome DNA. In this method, multiple restrictionenzyme digestions and ligations also can be used to place an engineereddouble-stranded sequence into an unknown fragment of the DNA moleculebefore performing PCR.

When screening for full-length cDNAs, it is preferable to use librariesthat have been size-selected to include larger cDNAs. Randomly-primedlibraries are preferable, in that they will contain more sequences whichcontain the 5′ regions of genes. Use of a randomly primed library may beespecially preferable for situations in which an oligo d(T) library doesnot yield a full-length cDNA. Genomic libraries can be useful forextension of sequence into 5′ non-transcribed regulatory regions.

Commercially available capillary electrophoresis systems can be used toanalyze the size or confirm the nucleotide sequence of PCR or sequencingproducts. For example, capillary sequencing can employ flowable polymersfor electrophoretic separation, four different fluorescent dyes (one foreach nucleotide) which are laser activated, and detection of the emittedwavelengths by a charge coupled device camera. Output/light intensitycan be converted to electrical signal using appropriate equipment andsoftware (e.g., GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and theentire process from loading of samples to computer analysis andelectronic data display can be computer controlled. Capillaryelectrophoresis is especially preferable for the sequencing of smallpieces of DNA which might be present in limited amounts in a particularsample.

Obtaining Polypeptides

FPRL1 can be obtained, for example, by purification from human cells, byexpression of FPRL1 polynucleotides, or by direct chemical synthesis.

Protein Purification

FPRL1 can be purified from any human cell which expresses the receptor,including those which have been transfected with expression constructswhich express FPRL1. A purified FPRL1 is separated from other compoundswhich normally associate with FPRL1 in the cell, such as certainproteins, carbohydrates, or lipids, using methods well-known in the art.Such methods include, but are not limited to, size exclusionchromatography, ammonium sulfate fractionation, ion exchangechromatography, affinity chromatography, and preparative gelelectrophoresis.

Expression of FPRL1 Polynucleotides

To express FPRL1, FPRL1 polynucleotides can be inserted into anexpression vector which contains the necessary elements for thetranscription and translation of the inserted coding sequence. Methodswhich are well known to those skilled in the art can be used toconstruct expression vectors containing sequences encoding FPRL1 andappropriate transcriptional and translational control elements. Thesemethods include in vitro recombinant DNA techniques, synthetictechniques, and in vivo genetic recombination.

A variety of expression vector/host systems can be utilized to containand express sequences encoding FPRL1. These include, but are not limitedto, microorganisms, such as bacteria transformed with recombinantbacteriophage, plasmid, or cosmid DNA expression vectors; yeasttransformed with yeast expression vectors, insect cell systems infectedwith virus expression vectors (e.g., baculovirus), plant cell systemstransformed with virus expression vectors (e.g., cauliflower mosaicvirus, CaMV; tobacco mosaic virus, TMV) or with bacterial expressionvectors (e.g., Ti or pBR322 plasmids), or animal cell systems.

The control elements or regulatory sequences are those non-translatedregions of the vector—enhancers, promoters, 5′ and 3′ untranslatedregions—which interact with host cellular proteins to carry outtranscription and translation. Such elements can vary in their strengthand specificity. Depending on the vector system and host utilized, anynumber of suitable transcription and translation elements, includingconstitutive and inducible promoters, can be used. For example, whencloning in bacterial systems, inducible promoters such as the hybridlacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.)or pSPORT1 plasmid (Life Technologies) and the like can be used. Thebaculovirus polyhedrin promoter can be used in insect cells. Promotersor enhancers derived from the genomes of plant cells (e.g., heat shock,RUBISCO, and storage protein genes) or from plant viruses (e.g, viralpromoters or leader sequences) can be cloned into the vector. Inmammalian cell systems, promoters from mammalian genes or from mammalianviruses are preferable. If it is necessary to generate a cell line thatcontains multiple copies of a nucleotide sequence encoding FPRL1,vectors based on SV40 or EBV can be used with an appropriate selectablemarker.

Bacterial and Yeast Expression Systems

In bacterial systems, a number of expression vectors can be selected.For example, when a large quantity of FPRL1 is needed for the inductionof antibodies, vectors which direct high level expression of fusionproteins that are readily purified can be used. Such vectors include,but are not limited to, multifunctional E. coli cloning and expressionvectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, asequence encoding FPRL1 can be ligated into the vector in frame withsequences for the amino-terminal Met and the subsequent 7 residues ofβ-galactosidase so that a hybrid protein is produced. pIN vectors orpGEX vectors (Promega, Madison, Wis.) also can be used to expressforeign polypeptides as fusion proteins with glutathione S-transferase(GST). In general, such fusion proteins are soluble and can easily bepurified from lysed cells by adsorption to glutathione-agarose beadsfollowed by elution in the presence of free glutathione. Proteins madein such systems can be designed to include heparin, thrombin, or factorXa protease cleavage sites so that the cloned polypeptide of interestcan be released from the GST moiety at will.

Plant and Insect Expression Systems

If plant expression vectors are used, the expression of sequencesencoding FPRL1 can be driven by any of a number of promoters. Forexample, viral promoters such as the 35S and 19S promoters of CAMV canbe used alone or in combination with the omega leader sequence from TMV.Alternatively, plant promoters such as the small subunit of RUBISCO orheat shock promoters can be used. These constructs can be introducedinto plant cells by direct DNA transformation or by pathogen-mediatedtransfection.

An insect system also can be used to express FPRL1. For example, in onesuch system Autographa californica nuclear polyhedrosis virus (AcNPV) isused as a vector to express foreign genes in Spodoptera frugiperda cellsor in Trichoplusia larvae. Sequences encoding FPRL1 can be cloned into anon-essential region of the virus, such as the polyhedrin gene, andplaced under control of the polyhedrin promoter. Successful insertion ofFPRL1 will render the polyhedrin gene inactive and produce recombinantvirus lacking coat protein. The recombinant viruses can then be used toinfect S. frugiperda cells or Trichoplusia larvae in which FPRL1 can beexpressed.

Mammalian Expression Systems

A number of viral-based expression systems can be used to express FPRL1in mammalian host cells. For example, if an adenovirus is used as anexpression vector, sequences encoding FPRL1 can be ligated into anadenovirus transcription/translation complex comprising the latepromoter and tripartite leader sequence. Insertion in a non-essential E1or E3 region of the viral genome can be used to obtain a viable viruswhich is capable of expressing FPRL1 in infected host cells [Engelhard,1994)]. If desired, transcription enhancers, such as the Rous sarcomavirus (RSV) enhancer, can be used to increase expression in mammalianhost cells.

Human artificial chromosomes (HACs) also can be used to deliver largerfragments of DNA than can be contained and expressed in a plasmid. HACsof 6M to 10M are constructed and delivered to cells via conventionaldelivery methods (e.g., liposomes, polycationic amino polymers, orvesicles). Specific initiation signals also can be used to achieve moreefficient translation of sequences encoding FPRL1. Such signals includethe ATG initiation codon and adjacent sequences. In cases wheresequences encoding FPRL1, its initiation codon, and upstream sequencesare inserted into the appropriate expression vector, no additionaltranscriptional or translational control signals may be needed. However,in cases where only coding sequence, or a fragment thereof, is inserted,exogenous translational control signals (including the ATG initiationcodon) should be provided. The initiation codon should be in the correctreading frame to ensure translation of the entire insert. Exogenoustranslational elements and initiation codons can be of various origins,both natural and synthetic.

Host Cells

A host cell strain can be chosen for its ability to modulate theexpression of the inserted sequences or to process the expressed FPRL1in the desired fashion. Such modifications of the polypeptide include,but are not limited to, acetylation, carboxylation, glycosylation,phosphorylation, lipidation, and acylation. Post-translationalprocessing which cleaves a “prepro” form of the polypeptide also can beused to facilitate correct insertion, folding and/or function. Differenthost cells which have specific cellular machinery and characteristicmechanisms for post-translational activities (e.g., CHO, HeLa, MDCK,HEK293, and WI38), are available from the American Type CultureCollection (ATCC; 10801 University Boulevard, Manassas, Va. 20110-2209)and can be chosen to ensure the correct modification and processing ofthe foreign protein.

Stable expression is preferred for long-term, high-yield production ofrecombinant proteins. For example, cell lines which stably express FPRL1can be transformed using expression vectors which can contain viralorigins of replication and/or endogenous expression elements and aselectable marker gene on the same or on a separate vector. Followingthe introduction of the vector, cells can be allowed to grow for 1-2days in an enriched medium before they are switched to a selectivemedium. The purpose of the selectable marker is to confer resistance toselection, and its presence allows growth and recovery of cells whichsuccessfully express the introduced FPRL1 sequences. Resistant clones ofstably transformed cells can be proliferated using tissue culturetechniques appropriate to the cell type. Any number of selection systemscan be used to recover transformed cell lines. These include, but arenot limited to, the herpes simplex virus thymidine kinase [Logan,(1984)] and adenine phosphoribosyltransferase [Wigler, (1977)] geneswhich can be employed in tk⁻ or aprt⁻ cells, respectively. Also,antimetabolite, antibiotic, or herbicide resistance can be used as thebasis for selection. For example, dhfr confers resistance tomethotrexate [Lowy, (1980)], npt confers resistance to theaminoglycosides, neomycin and G-418 [Wigler, (1980)], and als and patconfer resistance to chlorsulfuron and phosphinotricinacetyltransferase, respectively [Colbere-Garapin, 1981]. Additionalselectable genes have been described. For example, trpB allows cells toutilize indole in place of tryptophan, or hisD, which allows cells toutilize histinol in place of histidine [Murray, (1992)]. Visible markerssuch as anthocyanins, β-glucuronidase and its substrate GUS, andluciferase and its substrate luciferin, can be used to identifytransformants and to quantify the amount of transient or stable proteinexpression attributable to a specific vector system.

Detecting Polypeptide Expression

Although the presence of marker gene expression suggests that a FPRL1polynucleotide is also present, its presence and expression may need tobe confirmed. For example, if a sequence encoding FPRL1 is insertedwithin a marker gene sequence, transformed cells containing sequenceswhich encode FPRL1 can be identified by the absence of marker genefunction. Alternatively, a marker gene can be placed in tandem with asequence encoding FPRL1 under the control of a single promoter.Expression of the marker gene in response to induction or selectionusually indicates expression of FPRL1 polynucleotide.

Alternatively, host cells which contain a FPRL1 polynucleotide and whichexpress FPRL1 can be identified by a variety of procedures known tothose of skill in the art. These procedures include, but are not limitedto, DNA-DNA or DNA-RNA hybridizations and protein bioassay orimmunoassay techniques which include membrane, solution, or chip-basedtechnologies for the detection and/or quantification of nucleic acid orprotein. For example, the presence of a poly-nucleotide sequenceencoding FPRL1 can be detected by DNA-DNA or DNA-RNA hybridization oramplification using probes or fragments or fragments of polynucleotidesencoding FPRL1. Nucleic acid amplification-based assays involve the useof oligonucleotides selected from sequences encoding FPRL1 to detecttransformants which contain a FPRL1 polynucleotide.

A variety of protocols for detecting and measuring the expression ofFPRL1, using either polyclonal or monoclonal antibodies specific for thepolypeptide, are known in the art. Examples include enzyme-linkedimmunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescenceactivated cell sorting (FACS). A two-site, monoclonal-based immunoassayusing monoclonal antibodies reactive to two non-interfering epitopes onFPRL1 can be used, or a competitive binding assay can be employed.

A wide variety of labels and conjugation techniques are known by thoseskilled in the art and can be used in various nucleic acid and aminoacid assays. Means for producing labeled hybridization or PCR probes fordetecting sequences related to polynucleotides encoding FPRL1 includeoligolabeling, nick translation, end-labeling, or PCR amplificationusing a labeled nucleotide. Alternatively, sequences encoding FPRL1 canbe cloned into a vector for the production of an mRNA probe. Suchvectors are known in the art are commercially available, and can be usedto synthesize RNA probes in vitro by addition of labeled nucleotides andan appropriate RNA polymerase such as T7, T3, or SP6. These procedurescan be conducted using a variety of commercially available kits(Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitablereporter molecules or labels which can be used for ease of detectioninclude radionuclides, enzymes, and fluorescent, chemiluminescent, orchromogenic agents, as well as substrates, cofactors, inhibitors,magnetic particles, and the like.

Expression and Purification of Polypeptides

Host cells transformed with FPRL1 polynucleotides can be cultured underconditions suitable for the expression and recovery of the protein fromcell culture. The poly-peptide produced by a transformed cell can besecreted or contained intracellularly depending on the sequence and/orthe vector used. As will be understood by those of skill in the art,expression vectors containing FPRL1 polynucleotides can be designed tocontain signal sequences which direct secretion of soluble FPRL1 througha prokaryotic or eukaryotic cell membrane or which direct the membraneinsertion of membrane-bound FPRL1.

As discussed above, other constructions can be used to join a sequenceencoding FPRL1 to a nucleotide sequence encoding a polypeptide domainwhich will facilitate purification of soluble proteins. Suchpurification facilitating domains include, but are not limited to, metalchelating peptides such as histidine-tryptophan modules that allowpurification on immobilized metals, protein A domains that allowpurification on immobilized immunoglobulin, and the domain utilized inthe FLAGS extension/affinity purification system (Immunex Corp.,Seattle, Wash.). Inclusion of cleavable linker sequences such as thosespecific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.)between the purification domain and FPRL1 also can be used to facilitatepurification. One such expression vector provides for expression of afusion protein containing FPRL1 and 6 histidine residues preceding athioredoxin or an enterokinase cleavage site. The histidine residuesfacilitate purification by IMAC (immobilized metal ion affinitychromatography) Maddox, (1983)], while the enterokinase cleavage siteprovides a means for purifying FPRL1 from the fusion protein [Porath,(1992)].

Chemical Synthesis

Sequences encoding FPRL1 can be synthesized, in whole or in part, usingchemical methods well known in the art. Alternatively, FPRL1 itself canbe produced using chemical methods to synthesize its amino acidsequence, such as by direct peptide synthesis using solid-phasetechniques. Protein synthesis can either be performed using manualtechniques or by automation. Automated synthesis can be achieved, forexample, using Applied Biosystems 431A Peptide Synthesizer (PerkinElner). Optionally, fragments of FPRL1 can be separately synthesized andcombined using chemical methods to produce a full-length molecule.

The newly synthesized peptide can be substantially purified bypreparative high performance liquid chromatography. The composition of asynthetic FPRL1 can be confirmed by amino acid analysis or sequencing.Additionally, any portion of the amino acid sequence of FPRL1 can bealtered during direct synthesis and/or combined using chemical methodswith sequences from other proteins to produce a variant polypeptide or afusion protein.

Production of Altered Polypeptides

As will be understood by those of skill in the art, it may beadvantageous to produce FPRL1 polynucleotides possessing non-naturallyoccurring codons. For example, codons preferred by a particularprokaryotic or eukaryotic host can be selected to increase the rate ofprotein expression or to produce an RNA transcript having desirableproperties, such as a half-life which is longer than that of atranscript generated from the naturally occurring sequence.

The nucleotide sequences referred to herein can be engineered usingmethods generally known in the art to alter FPRL1 polynucleotides for avariety of reasons, including but not limited to, alterations whichmodify the cloning, processing, and/or expression of the polypeptide ormRNA product. DNA shuffling by random fragmentation and PCR reassemblyof gene fragments and synthetic oligonucleotides can be used to engineerthe nucleotide sequences. For example, site-directed mutagenesis can beused to insert new restriction sites, alter glycosylation patterns,change codon preference, produce splice variants, introduce mutations,and so forth.

Antibodies

Any type of antibody known in the art can be generated to bindspecifically to an epitope of FPRL1.

“Antibody” as used herein includes intact irMnunoglobulin molecules, aswell as fragments thereof, such as Fab, F(ab′)₂, and Fv, which arecapable of binding an epitope of FPRL1. Typically, at least 6, 8, 10, or12 contiguous amino acids are required to form an epitope. However,epitopes which involve non-contiguous amino acids may require more,e.g., at least 15, 25, or 50 amino acid. An antibody which specificallybinds to an epitope of FPRL1 can be used therapeutically, as well as inimmunochemical assays, such as Western blots, ELISAs, radioimmunoassays,immunohistochemical assays, immunoprecipitations, or otherimmunochemical assays known in the art. Various immunoassays can be usedto identify antibodies having the desired specificity. Numerousprotocols for competitive binding or immunoradiometric assays are wellknown in the art. Such immunoassays typically involve the measurement ofcomplex formation between an immunogen and an antibody whichspecifically binds to the FPRL1 immunogen.

Typically, an antibody which specifically binds to FPRL1 provides adetection signal at least 5-, 10-, or 20-fold higher than a detectionsignal provided with other proteins when used in an immunochemicalassay. Preferably, antibodies which specifically bind to FPRL1 do notdetect other proteins in immunochemical assays and can immunoprecipitateFPRL1 from solution.

FPRL1 can be used to immunize a mammal, such as a mouse, rat, rabbit,guinea pig, monkey, or human, to produce polyclonal antibodies. Ifdesired, FPRL1 can be conjugated to a carrier protein, such as bovineserum albumin, thyroglobulin, and keyhole limpet hemocyanin. Dependingon the host species, various adjuvants can be used to increase theimmunological response. Such adjuvants include, but are not limited to,Freund's adjuvant, mineral gels (e.g., aluminum hydroxide), and surfaceactive substances (e.g., lysolecithin, pluronic polyols, polyanions,peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol).Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) andCorynebacterium parvum are especially useful.

Monoclonal antibodies which specifically bind to FPRL1 can be preparedusing any technique which provides for the production of antibodymolecules by continuous cell lines in culture. These techniques include,but are not limited to, the hybridoma technique, the human B-cellhybridoma technique, and the EBV-hybridoma technique [Roberge, (1995)].

In addition, techniques developed for the production of “chimericantibodies”, the splicing of mouse antibody genes to human antibodygenes to obtain a molecule with appropriate antigen specificity andbiological activity, can be used. Monoclonal and other antibodies alsocan be “humanized” to prevent a patient from mounting an immune responseagainst the antibody when it is used therapeutically. Such antibodiesmay be sufficiently similar in sequence to human antibodies to be useddirectly in therapy or may require alteration of a few key residues.Sequence differences between rodent antibodies and human sequences canbe minimized by replacing residues which differ from those in the humansequences by site directed mutagenesis of individual residues or bygrating of entire complementarity determining regions. Antibodies whichspecifically bind to FPRL1 can contain antigen binding sites which areeither partially or fully humanized, as disclosed in U.S. Pat. No.5,565,332.

Alternatively, techniques described for the production of single chainantibodies can be adapted using methods known in the art to producesingle chain antibodies which specifically bind to FPRL1. Antibodieswith related specificity, but of distinct idiotypic composition, can begenerated by chain shuffling from random combinatorial immunoglobinlibraries. Single-chain antibodies also can be constructed using a DNAamplification method, such as PCR, using hybridoma cDNA as a template.Single-chain antibodies can be mono- or bispecific, and can be bivalentor tetravalent. Construction of tetravalent, bispecific single-chainantibodies is taught. A nucleotide sequence encoding a single-chainantibody can be constructed using manual or automated nucleotidesynthesis, cloned into an expression construct using standardrecombinant DNA methods, and introduced into a cell to express thecoding sequence, as described below. Alternatively, single-chainantibodies can be produced directly using, for example, filamentousphage technology.

Antibodies which specifically bind to FPRL1 also can be produced byinducing in vivo production in the lymphocyte population or by screeningimmunoglobulin libraries or panels of highly specific binding reagents.Other types of antibodies can be constructed and used therapeutically inmethods of the invention. For example, chimeric antibodies can beconstructed as disclosed in WO 93/03151. Binding proteins which arederived from immunoglobulins and which are multivalent andmulti-specific, such as the “diabodies” described in WO 94/13804, alsocan be prepared.

Antibodies according to the invention can be purified by methods wellknown in the art. For example, antibodies can be affinity purified bypassage over a column to which FPRL1 is bound. The bound antibodies canthen be eluted from the column using a buffer with a high saltconcentration.

Antisense Oligonucleotides

Antisense oligonucleotides are nucleotide sequences which arecomplementary to a specific DNA or RNA sequence. Once introduced into acell, the complementary nucleotides combine with natural sequencesproduced by the cell to form complexes and block either transcription ortranslation. Preferably, an antisense oligonucleotide is at least 11nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40,45, or 50 or more nucleotides long. Longer sequences also can be used.Antisense oligonucleotide molecules can be provided in a DNA constructand introduced into a cell as described above to decrease the level ofFPRL1 gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides,or a combination of both. Oligonucleotides can be synthesized manuallyor by an automated synthesizer, by covalently linking the 5′ end of onenucleotide with the 3′ end of another nucleotide with non-phosphodiesterinternucleotide linkages such alkyl-phosphonates, phosphorothioates,phosphorodithioates, alkylphosphonothioates, alkylphosphonates,phosphoramidates, phosphate esters, carbamates, acetamidate,carboxymethyl esters, carbonates, and phosphate triesters.

Modifications of FPRL1 gene expression can be obtained by designingantisense oligonucleotides which will form duplexes to the control, 5′,or regulatory regions of the FPRL1 gene. Oligonucleotides derived fromthe transcription initiation site, e.g., between positions −10 and +10from the start site, are preferred. Similarly, inhibition can beachieved using “triple helix” base-pairing methodology. Triple helixpairing is useful because it causes inhibition of the ability of thedouble helix to open sufficiently for the binding of polymerases,transcription factors, or chaperons. Therapeutic advances using triplexDNA have been described in the literature [Nicholls, (1993)]. Anantisense oligonucleotide also can be designed to block translation ofmRNA by preventing the transcript from binding to ribosomes.

Precise complementarity is not required for successful complex formationbetween an antisense oligonucleotide and the complementary sequence of aFPRL1 poly-nucleotide. Antisense oligonucleotides which comprise, forexample, 2, 3, 4, or 5 or more stretches of contiguous nucleotides whichare precisely complementary to a FPRL1 polynucleotide, each separated bya stretch of contiguous nucleotides which are not complementary toadjacent FPRL1 nucleotides, can provide sufficient targeting specificityfor FPRL1 mRNA. Preferably, each stretch of complementary contiguousnucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length.Non-complementary intervening sequences are preferably 1, 2, 3, or 4nucleotides in length. One skilled in the art can easily use thecalculated melting point of an anti-sense-sense pair to determine thedegree of mismatching which will be tolerated between a particularantisense oligonucleotide and a particular FPRL1 polynucleotidesequence. Antisense oligonucleotides can be modified without affectingtheir ability to hybridize to a FPRL1 polynucleotide. Thesemodifications can be internal or at one or both ends of the antisensemolecule. For example, internucleoside phosphate linkages can bemodified by adding cholesteryl or diamine moieties with varying numbersof carbon residues between the amino groups and terminal ribose.Modified bases and/or sugars, such as arabinose instead of ribose, or a3′,5′-substituted oligonucleotide in which the 3′ hydroxyl group or the5′ phosphate group are substituted, also can be employed in a modifiedantisense oligonucleotide. These modified oligonucleotides can beprepared by methods well known in the art.

Ribozynmes

Ribozymes are RNA molecules with catalytic activity [Uhlmann, (1987)].Ribozymes can be used to inhibit gene function by cleaving an RNAsequence, as is known in the art. The mechanism of ribozyme actioninvolves sequence-specific hybridization of the ribozyme molecule tocomplementary target RNA, followed by endonucleolytic cleavage. Examplesinclude engineered hammerhead motif ribozyme molecules that canspecifically and efficiently catalyze endonucleolytic cleavage ofspecific nucleotide sequences. The coding sequence of a FPRL1polynucleotide can be used to generate ribozymes which will specificallybind to mRNA transcribed from a FPRL1 polynucleotide. Methods ofdesigning and constructing ribozymes which can cleave other RNAmolecules in trans in a highly sequence specific manner have beendeveloped and described in the art. For example, the cleavage activityof ribozymes can be targeted to specific RNAs by engineering a discrete“hybridization” region into the ribozyme. The hybridization regioncontains a sequence complementary to the target RNA and thusspecifically hybridizes with the target RNA.

Specific ribozyme cleavage sites within a FPRL1 RNA target can beidentified by scanning the target molecule for ribozyme cleavage siteswhich include the following sequences: GUA, GUU, and GUC. Onceidentified, short RNA sequences of between 15 and 20 ribonucleotidescorresponding to the region of the target RNA containing the cleavagesite can be evaluated for secondary structural features which may renderthe target inoperable. Suitability of candidate FPRL1 RNA targets alsocan be evaluated by testing accessibility to hybridization withcomplementary oligonucleotides using ribonuclease protection assays. Thenucleotide sequences shown in SEQ ID NO: 1 and its complement providesources of suitable hybridization region sequences. Longer complementarysequences can be used to increase the affinity of the hybridizationsequence for the target. The hybridizing and cleavage regions of theribozyme can be integrally related such that upon hybridizing to thetarget RNA through the complementary regions, the catalytic region ofthe ribozyme can cleave the target.

Ribozymes can be introduced into cells as part of a DNA construct.Mechanical methods, such as microinjection, liposome-mediatedtransfection, electroporation, or calcium phosphate precipitation, canbe used to introduce a ribozyme-containing DNA construct into cells inwhich it is desired to decrease FPRL1 expression. Alternatively, if itis desired that the cells stably retain the DNA construct, the constructcan be supplied on a plasmid and maintained as a separate element orintegrated into the genome of the cells, as is known in the art. Aribozyme-encoding DNA construct can include transcriptional regulatoryelements, such as a promoter element, an enhancer or UAS element, and atranscriptional terminator signal, for controlling transcription ofribozymes in the cells (U.S. Pat. No. 5,641,673). Ribozymes also can beengineered to provide an additional level of regulation, so thatdestruction of mRNA occurs only when both a ribozyme and a target geneare induced in the cells.

Screening/Screening Assays

Regulators

Regulators as used herein, refer to compounds that affect the activityof a FPRL1 in vivo and/or in vivo. Regulators can be agonists andantagonists of a FPRL1 poly-peptide and can be compounds that exherttheir effect on the FPRL1 activity via the expression, viapost-translational modifications or by other means. Agonists of FPRL1are molecules which, when bound to FPRL1, increase or prolong theactivity of FPRL1. Agonists of FPRL1 include proteins, nucleic acids,carbohydrates, small molecules, or any other molecule which activateFPRL1. Antagonists of FPRL1 are molecules which, when bound to FPRL1,decrease the amount or the duration of the activity of FPRL1.Antagonists include proteins, nucleic acids, carbohydrates, antibodies,small molecules, or any other molecule which decrease the activity ofFPRL1.

The term “modulate”, as it appears herein, refers to a change in theactivity of FPRL1 polypeptide. For example, modulation may cause anincrease or a decrease in protein activity, binding characteristics, orany other biological, functional, or immunological properties of FPRL1.

As used herein, the terms “specific binding” or “specifically binding”refer to that interaction between a protein or peptide and an agonist,an antibody, or an antagonist. The interaction is dependent upon thepresence of a particular structure of the protein recognized by thebinding molecule (i.e., the antigenic determinant or epitope). Forexample, if an antibody is specific for epitope “A” the presence of apolypeptide containing the epitope A, or the presence of free unlabeledA, in a reaction containing free labeled A and the antibody will reducethe amount of labeled A that binds to the antibody.

The invention provides methods (also referred to herein as “screeningassays”) for identifying compounds which can be used for the treatmentof hematological and cardiovascular diseases, disorders of theperipheral and central nervous system, COPD, asthma, genito-urologicaldisorders and inflammation diseases. The methods entail theidentification of candidate or test compounds or agents (e.g., peptides,peptidomimetics, small molecules or other molecules) which bind to FPRL1and/or have a stimulatory or inhibitory effect on the biologicalactivity of FPRL1 or its expression and then determining which of thesecompounds have an effect on symtoms or diseases regarding thehematological and cardiovascular diseases, disorders of the peripheraland central nervous system, COPD, asthma, genitourological disorders andinflammation diseases in an in vivo assay.

Candidate or test compounds or agents which bind to FPRL1 and/or have astimulatory or inhibitory effect on the activity or the expression ofFPRL1 are identified either in assays that employ cells which expressFPRL1 on the cell surface (cell-based assays) or in assays with isolatedFPRL1 (cell-free assays). The various assays can employ a variety ofvariants of FPRL1 (e.g., full-length FPRL1, a biologically activefragment of FPRL1, or a fusion protein which includes all or a portionof FPRL1). Moreover, FPRL1 can be derived from any suitable mammalianspecies (e.g., human FPRL1, rat FPRL1 or murine FPRL1). The assay can bea binding assay entailing direct or indirect measurement of the bindingof a test compound or a known FPRL1 ligand to FPRL1. The assay can alsobe an activity assay entailing direct or indirect measurement of theactivity of FPRL1. The assay can also be an expression assay entailingdirect or indirect measurement of the expression of FPRL1 mRNA or FPRL1protein. The various screening assays are combined with an in vivo assayentailing measuring the effect of the test compound on the symtoms ofhematological and cardiovascular diseases, disorders of the peripheraland central nervous system, COPD, asthma, genito-urological disordersand inflammation diseases.

In one embodiment, the invention provides assays for screening candidateor test compounds which bind to or modulate the activity of amembrane-bound (cell surface expressed) form of FPRL1. Such assays canemploy full-length FPRL1, a biologically active fragment of FPRL1, or afusion protein which includes all or a portion of FPRL1. As described ingreater detail below, the test compound can be obtained by any suitablemeans, e.g., from conventional compound libraries. Determining theability of the test compound to bind to a membrane-bound form of FPRL1can be accomplished, for example, by coupling the test compound with aradioisotope or enzymatic label such that binding of the test compoundto the FPRL1-expressing cell can be measured by detecting the labeledcompound in a complex. For example, the test compound can be labelledwith ¹²⁵I, ³⁵S, ¹⁴C, or ³H, either directly or indirectly, and theradioisotope detected by direct counting of radio-emmission or byscintillation counting. Alternatively, the test compound can beenzymatically labelled with, for example, horseradish peroxidase,alkaline phosphatase, or luciferase, and the enzymatic label detected bydetermination of conversion of an appropriate substrate to product.

In a competitive binding format, the assay comprises contacting FPRL1expressing cell with a known compound which binds to FPRL1 to form anassay mixture, contacting the assay mixture with a test compound, anddetermining the ability of the test compound to interact with the FPRL1expressing cell, wherein determining the ability of the test compound tointeract with the FPRL1 expressing cell comprises determining theability of the test compound to preferentially bind the FPRL1 expressingcell as compared to the known compound.

In another embodiment, the assay is a cell-based assay comprisingcontacting a cell expressing a membrane-bound form of FPRL1 (e.g.,full-length FPRL1, a biologically active fragment of FPRL1, or a fusionprotein which includes all or a portion of FPRL1) expressed on the cellsurface with a test compound and determining the ability of the testcompound to modulate (e.g., stimulate or inhibit) the activity of themembrane-bound form of FPRL1. Determining the ability of the testcompound to modulate the activity of the membrane-bound form of FPRL1can be accomplished by any method suitable for measuring the activity ofFPRL1, e.g., any method suitable for measuring the activity of aG-protein coupled receptor or other seven-transmembrane receptor(described in greater detail below). The activity of aseven-transmembrane receptor can be measured in a number of ways, notall of which are suitable for any given receptor. Among the measures ofactivity are: alteration in intracellular Ca²⁺ concentration, activationof phospholipase C, alteration in intracellular inositol triphosphate(IP₃) concentration, alteration in intracellular diacylglycerol (DAG)concentration, and alteration in intracellular adenosine cyclic3′,5′-monophosphate (cAMP) concentration.

Determining the ability of the test compound to modulate the activity ofFPRL1 can be accomplished, for example, by determining the ability ofFPRL1 to bind to or interact with a target molecule. The target moleculecan be a molecule with which FPRL1 binds or interacts with in nature,for example, a molecule on the surface of a cell which expresses FPRL1,a molecule on the surface of a second cell, a molecule in theextracellular milieu, a molecule associated with the internal surface ofa cell membrane or a cytoplasmic molecule. The target molecule can be acomponent of a signal transduction pathway which facilitatestransduction of an extracellular signal (e.g., a signal generated bybinding of a FPRL1-ligand, through the cell membrane and into the cell.The target FPRL1 molecule can be, for example, a second intracellularprotein which has catalytic activity or a protein which facilitates theassociation of downstream signaling molecules with FPRL1.

Determining the ability of FPRL1 to bind to or interact with a targetmolecule can be accomplished by one of the methods described above fordetermining direct binding. In one embodiment, determining the abilityof a polypeptide of the invention to bind to or interact with a targetmolecule can be accomplished by determining the activity of the targetmolecule. For example, the activity of the target molecule can bedetermined by detecting induction of a cellular second messenger of thetarget (e.g., intra-cellular Ca²⁺, diacylglycerol, IP₃, etc.), detectingcatalytic/enzymatic activity of the target on an appropriate substratedetecting the induction of a reporter gene (e.g., a regulatory elementthat is responsive to a polypeptide of the invention operably linked toa nucleic acid encoding a detectable marker, e.g., luciferase), ordetecting a cellular response.

The present invention also includes cell-free assays. Such assaysinvolve contacting a form of FPRL1 (e.g., full-length FPRL1, abiologically active fragment of FPRL1, or a fusion protein comprisingall or a portion of FPRL1) with a test compound and determining theability of the test compound to bind to FPRL1. Binding of the testcompound to FPRL1 can be determined either directly or indirectly asdescribed above. In one embodiment, the assay includes contacting FPRL1with a known compound which binds FPRL1 to form an assay mixture,contacting the assay mixture with a test compound, and determining theability of the test compound to interact with FPRL1, wherein determiningthe ability of the test compound to interact with FPRL1 comprisesdetermining the ability of the test compound to preferentially bind toFPRL1 as compared to the known compound.

The cell-free assays of the present invention are amenable to use ofeither a membrane-bound form of FPRL1 or a soluble fragment thereof. Inthe case of cell-free assays comprising the membrane-bound form of thepolypeptide, it may be desirable to utilize a solubilizing agent suchthat the membrane-bound form of the polypeptide is maintained insolution. Examples of such solubilizing agents include but are notlimited to non-ionic detergents such as n-octylglucoside,n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide,decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit,Isotridecypoly(ethylene glycol ether)n,3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS),3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate(CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In various embodiments of the above assay methods of the presentinvention, it may be desirable to immobilize FPRL1 (or a FPRL1 targetmolecule) to facilitate separation of complexed from uncomplexed formsof one or both of the proteins, as well as to accommodate automation ofthe assay. Binding of a test compound to FPRL1, or interaction of FPRL1with a target molecule in the presence and absence of a candidatecompound, can be accomplished in any vessel suitable for containing thereactants. Examples of such vessels include microtitre plates, testtubes, and micro-centrifuge tubes. In one embodiment, a fusion proteincan be provided which adds a domain that allows one or both of theproteins to be bound to a matrix. For example, glutathione-S-transferase(GST) fusion proteins or glutathione-S-transferase fusion proteins canbe adsorbed onto glutathione sepharose beads (Sigma Chemical; St. Louis,Mo.) or glutathione derivatized microtitre plates, which are thencombined with the test compound or the test compound and either thenon-adsorbed target protein or FPRL1, and the mixture incubated underconditions conducive to complex formation (e.g., at physiologicalconditions for salt and pH). Following incubation, the beads ormicrotitre plate wells are washed to remove any unbound components andcomplex formation is measured either directly or indirectly, forexample, as described above. Alternatively, the complexes can bedissociated from the matrix, and the level of binding or activity ofFPRL1 can be determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be usedin the screening assays of the invention. For example, either FPRL1 orits target molecule can be immobilized utilizing conjugation of biotinand streptavidin. Biotinylated polypeptide of the invention or targetmolecules can be prepared from biotin-NHS (N-hydroxy-succinimide) usingtechniques well known in the art (e.g., biotinylation kit, PierceChemicals; Rockford, Ill.), and immobilized in the wells ofstreptavidin-coated plates (Pierce Chemical). Alternatively, antibodiesreactive with FPRL1 or target molecules but which do not interfere withbinding of the polypeptide of the invention to its target molecule canbe derivatized to the wells of the plate, and unbound target orpolypeptide of the invention trapped in the wells by antibodyconjugation. Methods for detecting such complexes, in addition to thosedescribed above for the GST-immobilized complexes, includeimmunodetection of complexes using antibodies reactive with FPRL1 ortarget molecule, as well as enzyme-linked assays which rely on detectingan enzymatic activity associated with FPRL1 or target molecule.

The screening assay can also involve monitoring the expression of FPRL1.For example, regulators of expression of FPRL1 can be identified in amethod in which a cell is contacted with a candidate compound and theexpression of FPRL1 protein or mRNA in the cell is determined. The levelof expression of FPRL1 protein or mRNA the presence of the candidatecompound is compared to the level of expression of FPRL1 protein or mRNAin the absence of the candidate compound. The candidate compound canthen be identified as a regulator of expression of FPRL1 based on thiscomparison. For example, when expression of FPRL1 protein or mRNAprotein is greater (statistically significantly greater) in the presenceof the candidate compound than in its absence, the candidate compound isidentified as a stimulator of FPRL1 protein or mRNA expression.Alternatively, when expression of FPRL1 protein or mRNA is less(statistically significantly less) in the presence of the candidatecompound than in its absence, the candidate compound is identified as aninhibitor of FPRL1 protein or mRNA expression. The level of FPRL1protein or mRNA expression in the cells can be determined by methodsdescribed below.

Binding Assays

For binding assays, the test compound is preferably a small moleculewhich binds to and occupies the active site of FPRL1 polypeptide,thereby making the ligand binding site inaccessible to substrate suchthat normal biological activity is prevented. Examples of such smallmolecules include, but are not limited to, small peptides orpeptide-like molecules. Potential ligands which bind to a polypeptide ofthe invention include, but are not limited to, the natural ligands ofknown FPRL1 GPCRs and analogues or derivatives thereof.

In binding assays, either the test compound or the FPRL1 polypeptide cancomprise a detectable label, such as a fluorescent, radioisotopic,chemiluminescent, or enzymatic label, such as horseradish peroxidase,alkaline phosphatase, or luciferase. Detection of a test compound whichis bound to FPRL1 polypeptide can then be accomplished, for example, bydirect counting of radioemmission, by scintillation counting, or bydetermining conversion of an appropriate substrate to a detectableproduct. Alternatively, binding of a test compound to a FPRL1polypeptide can be determined without labeling either of theinteractants. For example, a microphysiometer can be used to detectbinding of a test compound with a FPRL1 polypeptide. A micro-physiometer(e.g., Cytosensor™) is an analytical instrument that measures the rateat which a cell acidifies its environment using a light-addressablepotentiometric sensor (LAPS). Changes in this acidification rate can beused as an indicator of the interaction between a test compound andFPRL1 [Haseloff, (1988)].

Determining the ability of a test compound to bind to FPRL1 also can beaccomplished using a technology such as real-time BimolecularInteraction Analysis (BIA) [McConnell, (1992); Sjolander, (1991)]. BIAis a technology for studying biospecific interactions in real time,without labeling any of the interactants (e.g., BIAcore™). Changes inthe optical phenomenon surface plasmon resonance (SPR) can be used as anindication of real-time reactions between biological molecules.

In yet another aspect of the invention, a FPRL1-like polypeptide can beused as a “bait protein” in a two-hybrid assay or three-hybrid assay[Szabo, (1995); U.S. Pat. No. 5,283,317), to identify other proteinswhich bind to or interact with FPRL1 and modulate its activity.

The two-hybrid system is based on the modular nature of mosttranscription factors, which consist of separable DNA-binding andactivation domains. Briefly, the assay utilizes two different DNAconstructs. For example, in one construct, polynucleotide encoding FPRL1can be fused to a polynucleotide encoding the DNA binding domain of aknown transcription factor (e.g., GAL-4). In the other construct a DNAsequence that encodes an unidentified protein (“prey” or “sample”) canbe fused to a polynucleotide that codes for the activation domain of theknown transcription factor. If the “bait” and the “prey” proteins areable to interact in vivo to form an protein-dependent complex, theDNA-binding and activation domains of the transcription factor arebrought into close proximity. This proximity allows transcription of areporter gene (e.g., LacZ), which is operably linked to atranscriptional regulatory site responsive to the transcription factor.Expression of the reporter gene can be detected, and cell coloniescontaining the functional transcription factor can be isolated and usedto obtain the DNA sequence encoding the protein which interacts withFPRL1.

It may be desirable to immobilize either the FPRL1 (or polynucleotide)or the test compound to facilitate separation of the bound form fromunbound forms of one or both of the interactants, as well as toaccommodate automation of the assay. Thus, either the FPRL1-likepolypeptide (or polynucleotide) or the test compound can be bound to asolid support. Suitable solid supports include, but are not limited to,glass or plastic slides, tissue culture plates, microtiter wells, tubes,silicon chips, or particles such as beads (including, but not limitedto, latex, polystyrene, or glass beads). Any method known in the art canbe used to attach FPRL1-like polypeptide (or polynucleotide) or testcompound to a solid support, including use of covalent and non-covalentlinkages, passive absorption, or pairs of binding moieties attachedrespectively to the polypeptide (or polynucleotide) or test compound andthe solid support. Test compounds are preferably bound to the solidsupport in an array, so that the location of individual test compoundscan be tracked. Binding of a test compound to FPRL1 (or a polynucleotideencoding for FPRL1) can be accomplished in any vessel suitable forcontaining the reactants. Examples of such vessels include microtiterplates, test tubes, and microcentrifuge tubes.

In one embodiment, FPRL1 is a fusion protein comprising a domain thatallows binding of FPRL1 to a solid support. For example,glutathione-S-transferase fusion proteins can be adsorbed ontoglutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) orglutathione derivatized microtiter plates, which are then combined withthe test compound or the test compound and the non-adsorbed FPRL1; themixture is then incubated under conditions conducive to complexformation (e.g., at physiological conditions for salt and pH). Followingincubation, the beads or microtiter plate wells are washed to remove anyunbound components. Binding of the interactants can be determined eitherdirectly or indirectly, as described above. Alternatively, the complexescan be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solidsupport also can be used in the screening assays of the invention. Forexample, either FPRL1 (or a polynucleotide encoding FPRL1) or a testcompound can be immobilized utilizing conjugation of biotin andstreptavidin. Biotinylated FPRL1 (or a polynucleotide encodingbiotinylated FPRL1) or test compounds can be prepared from biotin-NHS(N-hydroxysuccinimide) using techniques well known in the art (e.g,biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized inthe wells of streptavidin-coated plates (Pierce Chemical).Alternatively, antibodies which specifically bind to FPRL1,polynucleotide, or a test compound, but which do not interfere with adesired binding site, such as the active site of FPRL1, can bederivatized to the wells of the plate. Unbound target or protein can betrapped in the wells by antibody conjugation. Methods for detecting suchcomplexes, in addition to those described above for the GST-immobilizedcomplexes, include immunodetection of complexes using anti-bodies whichspecifically bind to FPRL1 polypeptide or test compound, enzyme-linkedassays which rely on detecting an activity of FPRL1 polypeptide, and SDSgel electrophoresis under non-reducing conditions.

Screening for test compounds which bind to a FPRL1 polypeptide orpolynucleotide also can be carried out in an intact cell. Any cell whichcomprises a FPRL1 polypeptide or polynucleotide can be used in acell-based assay system. A FPRL1 polynucleotide can be naturallyoccurring in the cell or can be introduced using techniques such asthose described above. Binding of the test compound to FPRL1 or apolynucleotide encoding FPRL1 is determined as described above.

Functional Assays

Test compounds can be tested for the ability to increase or decreaseFPRL1 activity of a FPRL1 polypeptide. The FPRL1 activity can bemeasured, for example, using methods described in the specific examples,below. FPRL1 activity can be measured after contacting either a purifiedFPRL1, a cell membrane preparation, or an intact cell with a testcompound. A test compound which decreases FPRL1 activity by at leastabout 10, preferably about 50, more preferably about 75, 90, or 100% isidentified as a potential agent for decreasing FPRL1 activity. A testcompound which increases FPRL1 activity by at least about 10, preferablyabout 50, more preferably about 75, 90, or 100% is identified as apotential agent for increasing FPRL1 activity.

One such screening procedure involves the use of melanophores which aretransfected to express FPRL1. Such a screening technique is described inPCT WO 92/01810 published Feb. 6, 1992. Thus, for example, such an assaymay be employed for screening for a compound which inhibits activationof the receptor polypeptide of the present invention by contacting themelanophore cells which encode the receptor with both the receptorligand and a compound to be screened. Inhibition of the signal generatedby the ligand indicates that a compound is a potential antagonist forthe receptor, i.e., inhibits activation of the receptor. The screen maybe employed for identifying a compound which activates the receptor bycontacting such cells with compounds to be screened and determiningwhether each compound generates a signal, i.e., activates the receptor.

Other screening techniques include the use of cells which express FPRL1(for example, transfected CHO cells) in a system which measuresextracellular pH changes caused by receptor activation [Iwabuchi,(1993)]. For example, compounds may be contacted with a cell whichexpresses the receptor polypeptide of the present invention and a secondmessenger response, e.g., signal transduction or pH changes, can bemeasured to determine whether the potential compound activates orinhibits the receptor. Another such screening technique involvesintroducing RNA encoding FPRL1 into Xenopus oocytes to transientlyexpress the receptor. The receptor oocytes can then be contacted withthe receptor ligand and a compound to be screened, followed by detectionof inhibition or activation of a calcium signal in the case of screeningfor compounds which are thought to inhibit activation of the receptor.

Another screening technique involves expressing FPRL1 in cells in whichthe receptor is linked to a phospholipase C or D. Such cells includeendothelial cells, smooth muscle cells, embryonic kidney cells, etc. Thescreening may be accomplished as described above by quantifying thedegree of activation of the receptor from changes in the phospholipaseactivity.

Gene Expression

In another embodiment, test compounds which increase or decrease FPRL1gene expression are identified. As used herein, the term “correlateswith expression of a polynucleotide” indicates that the detection of thepresence of nucleic acids, the same or related to a nucleic acidsequence encoding FPRL1, by northern analysis or relatime PCR isindicative of the presence of nucleic acids encoding FPRL1 in a sample,and thereby correlates with expression of the transcript from thepolynucleotide encoding FPRL1. The term “microarray”, as used herein,refers to an array of distinct polynucleotides or oligonucleotidesarrayed on a substrate, such as paper, nylon or any other type ofmembrane, filter, chip, glass slide, or any other suitable solidsupport. A FPRL1 polynucleotide is contacted with a test compound, andthe expression of an RNA or polypeptide product of FPRL1 polynucleotideis determined. The level of expression of appropriate mRNA orpolypeptide in the presence of the test compound is compared to thelevel of expression of mRNA or polypeptide in the absence of the testcompound. The test compound can then be identified as a regulator ofexpression based on this comparison. For example, when expression ofmRNA or polypeptide is greater in the presence of the test compound thanin its absence, the test compound is identified as a stimulator orenhancer of the mRNA or polypeptide expression. Alternatively, whenexpression of the mRNA or polypeptide is less in the presence of thetest compound than in its absence, the test compound is identified as aninhibitor of the mRNA or polypeptide expression.

The level of FPRL1 mRNA or polypeptide expression in the cells can bedetermined by methods well known in the art for detecting mRNA orpolypeptide. Either qualitative or quantitative methods can be used. Thepresence of polypeptide products of FPRL1 polynucleotide can bedetermined, for example, using a variety of techniques known in the art,including immunochemical methods such as radio-immunoassay, Westernblotting, and immunohistochemistry. Alternatively, polypeptide synthesiscan be determined in vivo, in a cell culture, or in an in vitrotranslation system by detecting incorporation of labelled amino acidsinto FPRL1.

Such screening can be carried out either in a cell-free assay system orin an intact cell. Any cell which expresses FPRL1 polynucleotide can beused in a cell-based assay system. The FPRL1 polynucleotide can benaturally occurring in the cell or can be introduced using techniquessuch as those described above. Either a primary culture or anestablished cell line can be used.

Test Compounds

Suitable test compounds for use in the screening assays of the inventioncan be obtained from any suitable source, e.g., conventional compoundlibraries. The test compounds can also be obtained using any of thenumerous approaches in combinatorial library methods known in the art,including: biological libraries; spatially addressable parallel solidphase or solution phase libraries; synthetic library methods requiringdeconvolution; the “one-bead one-compound” library method; and syntheticlibrary methods using affinity chromatography selection. The biologicallibrary approach is limited to peptide libraries, while the other fourapproaches are applicable to peptide, non-peptide oligomer or smallmolecule libraries of compounds [Lam, (1997)]. Examples of methods forthe synthesis of molecular libraries can be found in the art. Librariesof compounds may be presented in solution or on beads, bacteria, spores,plasmids or phage.

Modeling of Regulators

Computer modeling and searching technologies permit identification ofcompounds, or the improvement of already identified compounds, that canmodulate FPRL1 expression or activity. Having identified such a compoundor composition, the active sites or regions are identified. Such activesites might typically be ligand binding sites, such as the interactiondomain of the ligand with FPRL1. The active site can be identified usingmethods known in the art including, for example, from the amino acidsequences of peptides, from the nucleotide sequences of nucleic acids,or from study of complexes of the relevant compound or composition withits natural ligand. In the latter case, chemical or X-raycrystallographic methods can be used to find the active site by findingwhere on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site isdetermined. This can be done by known methods, including X-raycrystallography, which can determine a complete molecular structure. Onthe other hand, solid or liquid phase NMR can be used to determinecertain intramolecular distances. Any other experimental method ofstructure determination can be used to obtain partial or completegeometric structures. The geometric structures may be measured with acomplexed ligand, natural or artificial, which may increase the accuracyof the active site structure determined.

If an incomplete or insufficiently accurate structure is determined, themethods of computer based numerical modeling can be used to complete thestructure or improve its accuracy. Any recognized modeling method may beused, including parameterized models specific to particular biopolymerssuch as proteins or nucleic acids, molecular dynamics models based oncomputing molecular motions, statistical mechanics models based onthermal ensembles, or combined models. For most types of models,standard molecular force fields, representing the forces betweenconstituent atoms and groups, are necessary, and can be selected fromforce fields known in physical chemistry. The incomplete or lessaccurate experimental structures can serve as constraints on thecomplete and more accurate structures computed by these modelingmethods.

Finally, having determined the structure of the active site, eitherexperimentally, by modeling, or by a combination, candidate modulatingcompounds can be identified by searching databases containing compoundsalong with information on their molecular structure. Such a search seekscompounds having structures that match the determined active sitestructure and that interact with the groups defining the active site.Such a search can be manual, but is preferably computer assisted. Thesecompounds found from this search are potential FPRL1 modulatingcompounds.

Alternatively, these methods can be used to identify improved modulatingcompounds from an already known modulating compound or ligand. Thecomposition of the known compound can be modified and the structuraleffects of modification can be determined using the experimental andcomputer modeling methods described above applied to the newcomposition. The altered structure is then compared to the active sitestructure of the compound to determine if an improved fit or interactionresults. In this manner systematic variations in composition, such as byvarying side groups, can be quickly evaluated to obtain modifiedmodulating compounds or ligands of improved specificity or activity.

Therapeutic Indications and Methods

It was found by the present applicant that FPRL1 is expressed in varioushuman tissues.

Central Nervous System (CNS) Disorders

CNS disorders include disorders of the central nervous system as well asdisorders of the peripheral nervous system.

CNS disorders include, but are not limited to brain injuries,cerebrovascular diseases and their consequences, Parkinson's disease,corticobasal degeneration, motor neuron disease, dementia, includingALS, multiple sclerosis, traumatic brain injury, stroke, post-stroke,post-traumatic brain injury, and small-vessel cerebrovascular disease.Dementias, such as Alzheimer's disease, vascular dementia, dementia withLewy bodies, frontotemporal dementia and Parkinsonism linked tochromosome 17, frontotemporal dementias, including Pick's disease,progressive nuclear palsy, corticobasal degeneration, Huntington'sdisease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia,schizophrenia with dementia, and Korsakoff's psychosis, within themeaning of the definition are also considered to be CNS disorders.

Similarly, cognitive-related disorders, such as mild cognitiveimpairment, age-associated memory impairment, age-related cognitivedecline, vascular cognitive impairment, attention deficit disorders,attention deficit hyperactivity disorders, and memory disturbances inchildren with learning disabilities are also considered to be CNSdisorders.

Pain, within the meaning of this definition, is also considered to be aCNS disorder. Pain can be associated with CNS disorders, such asmultiple sclerosis, spinal cord injury, sciatica, failed back surgerysyndrome, traumatic brain injury, epilepsy, Parkinson's disease,post-stroke, and vascular lesions in the brain and spinal cord (e.g.,infarct, hemorrhage, vascular malformation). Non-central neuropathicpain includes that associated with post mastectomy pain, phantomfeeling, reflex sympathetic dystrophy (RSD), trigeminalneuralgiaradioculopathy, post-surgical pain, HIV/AIDS related pain,cancer pain, metabolic neuropathies (e.g., diabetic neuropathy,vasculitic neuropathy secondary to connective tissue disease),paraneoplastic polyneuropathy associated, for example, with carcinoma oflung, or leukemia, or lymphoma, or carcinoma of prostate, colon orstomach, trigeminal neuralgia, cranial neuralgias, and post-herpeticneuralgia. Pain associated with peripheral nerve damage, central pain(i.e. due to cerebral ischemia) and various chronic pain i.e., lumbago,back pain (low back pain), inflammatory and/or rheumatic pain. Headachepain (for example, migraine with aura, migraine without aura, and othermigraine disorders), episodic and chronic tension-type headache,tension-type like headache, cluster headache, and chronic paroxysmalhemicrania are also CNS disorders.

Visceral pain such as pancreatits, intestinal cystitis, dysmenorrhea,irritable Bowel syndrome, Crohn's disease, biliary colic, ureteralcolic, myocardial infarction and pain syndromes of the pelvic cavity,e.g., vulvodynia, orchialgia, urethral syndrome and protatodynia arealso CNS disorders.

Also considered to be a disorder of the nervous system are acute pan,for example postoperative pain, and pain after trauma.

FPRL1 is highly expressed in various brain tissues such as cerebellum(total, right, left), parietal lobe, precentral gyrus, thalamus,cerebral cortex, frontal lobe, temporal lobe, postcentral gyrus,tonsilla cerebelli, vermis cerebelli, cerebral peduncles, hippocampus.The expression in the above mentioned tissues suggests an association ofFPRL1 with nervous system diseases.

FPRL1 can be used to treat or to diagnose nervous system diseases.

Cardiovascular Disorders

Heart failure is defined as a pathophysiological state in which anabnormality of cardiac function is responsible for the failure of theheart to pump blood at a rate commensurate with the requirement of themetabolizing tissue. It includes all forms of pumping failures such ashigh-output and low-output, acute and chronic, right-sided orleft-sided, systolic or diastolic, independent of the underlying cause.

Myocardial infarction (MI) is generally caused by an abrupt decrease incoronary blood flow that follows a thrombotic occlusion of a coronaryartery previously narrowed by arteriosclerosis. MI prophylaxis (primaryand secondary prevention) is included as well as the acute treatment ofMI and the prevention of complications.

Ischemic diseases are conditions in which the coronary flow isrestricted resulting in a perfusion which is inadequate to meet themyocardial requirement for oxygen. This group of diseases includesstable angina, unstable angina and asymptomatic ischema.

Arrhythmias include all forms of atrial and ventriculartachyarrhythmias, atrial tachycardia, atrial flutter, atrialfibrillation, atrio-ventricular reentrant tachycardia, preexitationsyndrome, ventricular tachycardia, ventricular flutter, ventricularfibrillation, as well as bradycardic forms of arrhythmias.

Hypertensive vascular diseases include primary as well as all kinds ofsecondary arterial hypertension, renal, endocrine, neurogenic, others.The genes may be used as drug targets for the treatment of hypertensionas well as for the prevention of all complications arising fromcardiovascular diseases.

Peripheral vascular diseases are defined as vascular diseases in whicharterial and/or venous flow is reduced resulting in an imbalance betweenblood supply and tissue oxygen demand. It includes chronic peripheralarterial occlusive disease (PAOD), acute arterial thrombosis andembolism, inflammatory vascular disorders, Raynaud's phenomenon andvenous disorders.

Atherosclerosis is a cardiovascular disease in which the vessel wall isremodeled, compromising the lumen of the vessel. The atheroscleroticremodeling process involves accumulation of cells, both smooth musclecells and monocyte/macrophage inflammatory cells, in the intima of thevessel wall. These cells take up lipid, likely from the circulation, toform a mature atherosclerotic lesion. Although the formation of theselesions is a chronic process, occurring over decades of an adult humanlife, the majority of the morbidity associated with atherosclerosisoccurs when a lesion ruptures, releasing thrombogenic debris thatrapidly occludes the artery. When such an acute event occurs in thecoronary artery, myocardial infarction can ensue, and in the worst case,can result in death.

The formation of the atherosclerotic lesion can be considered to occurin five overlapping stages such as migration, lipid accumulation,recruitment of inflammatory cells, proliferation of vascular smoothmuscle cells, and extracellular matrix deposition. Each of theseprocesses can be shown to occur in man and in animal models ofatherosclerosis, but the relative contribution of each to the pathologyand clinical significance of the lesion is unclear.

Thus, a need exists for therapeutic methods and agents to treatcardiovascular pathologies, such as atherosclerosis and other conditionsrelated to coronary artery disease.

Cardiovascular diseases include but are not limited to disorders of theheart and the vascular system like congestive heart failure, myocardialinfarction, ischemic diseases of the heart, all kinds of atrial andventricular arrhythmias, hypertensive vascular diseases, peripheralvascular diseases, and atherosclerosis.

FPRL1 is highly expressed in different cardiovascular related tissuessuch as heart, aorta, sclerotic aorta, and vein. Expression in the abovementioned tissues suggests an association between FPRL1 andcardiovascular diseases. FPRL1 can be regulated to treat or to diagnosecardiovascular diseases.

Hematological Disorders

Hematological disorders comprise diseases of the blood and all itsconstituents as well as diseases of organs and tissues involved in thegeneration or degradation of all the constituents of the blood. Theyinclude but are not limited to 1) Anemias, 2) MyeloproliferativeDisorders, 3) Hemorrhagic Disorders, 4) Leukopenia, 5) EosinophilicDisorders, 6) Leukemias, 7) Lymphomas, 8) Plasma Cell Dyscrasias, 9)Disorders of the Spleen in the course of hematological disorders.Disorders according to 1) include, but are not limited to anemias due todefective or deficient hem synthesis, deficient erythropoiesis.Disorders according to 2) include, but are not limited to polycythemiavera, tumor-associated erythrocytosis, myelofibrosis, thrombocythemia.Disorders according to 3) include, but are not limited to vasculitis,thrombocytopenia, heparin-induced thrombocytopenia, thromboticthrombocytopenic purpura, hemolytic-uremic syndrome, hereditary andacquired disorders of platelet function, hereditary coagulationdisorders. Disorders according to 4) include, but are not limited toneutropenia, lymphocytopenia Disorders according to 5) include, but arenot limited to hypereosinophilia, idiopathic hypereosinophilic syndrome.

Disorders according to 6) include, but are not limited to acute myeloicleukemia, acute lymphoblastic leukemia, chronic myelocytic leukemia,chronic lymphocytic leukemia, myelodysplastic syndrome. Disordersaccording to 7) include, but are not limited to Hodgkin's disease,non-Hodgkin's lymphoma, Burkitt's lymphoma, mycosis fungoides cutaneousT-cell lymphoma. Disorders according to 8) include, but are not limitedto multiple myeloma, macroglobulinemia, heavy chain diseases. Inextension of the preceding idiopathic thrombocytopenic purpura, irondeficiency anemia, megaloblastic anemia (vitamin B12 deficiency),aplastic anemia, thalassemia, malignant lymphoma bone marrow invasion,malignant lymphoma slcin invasion, hemolytic uremic syndrome, giantplatelet disease are considered to be hematological diseases too.

FPRL1 is highly expressed in erythrocytes and other tissues of thehematological system. The expression in the above mentioned tissuessuggests an association between FPRL1 and hematological diseases. FPRL1can be regulated in order to treat or to diagnose hematologicaldisorders.

Asthma and COPD Disorders

Asthma is thought to arise as a result of interactions between multiplegenetic and environmental factors and is characterized by three majorfeatures: 1) intermittent and reversible airway obstruction caused bybronchoconstriction, increased mucus production, and thickening of thewalls of the airways that leads to a narrowing of the airways, 2) airwayhyperresponsiveness, and 3) airway inflammation. Certain cells arecritical to the inflammatory reaction of asthma and they include T cellsand antigen presenting cells, B cells that produce IgE, and mast cells,basophils, eosinophils, and other cells that bind IgE. These effectorcells accumulate at the site of allergic reaction in the airways andrelease toxic products that contribute to the acute pathology andeventually to tissue destruction related to the disorder. Other residentcells, such as smooth muscle cells, lung epithelial cells,mucus-producing cells, and nerve cells may also be abnormal inindividuals with asthma and may contribute to its pathology. While theairway obstruction of asthma, presenting clinically as an intermittentwheeze and shortness of breath, is generally the most pressing symptomof the disease requiring immediate treatment, the inflammation andtissue destruction associated with the disease can lead to irreversiblechanges that eventually make asthma a chronic and disabling disorderrequiring long-term management.

Chronic obstructive pulmonary (or airways) disease (COPD) is a conditiondefined physiologically as airflow obstruction that generally resultsfrom a mixture of emphysema and peripheral airway obstruction due tochronic bronchitis [Botstein, 1980]. Emphysema is characterised bydestruction of alveolar walls leading to abnormal enlargement of the airspaces of the lung. Chronic bronchitis is defined clinically as thepresence of chronic productive cough for three months in each of twosuccessive years. In COPD, airflow obstruction is usually progressiveand is only partially reversible. By far the most important risk factorfor development of COPD is cigarette smoking, although the disease doesalso occur in non-smokers.

FPRL1 is highly expressed in respiratory tissues, lung in the state ofChronic Obstructive Pulmonary Disease (COPD). The expression of FPRL1 inCOPD affected lung is higher than in healthy lung. The expression ofFPRL1 in the above mentioned tissues suggests an association betweenFPRL1 and respiratory diseases such as asthma and COPD, and therapeuticregulation of the FPRL1 receptor can be used to treat disorders of therespiratory system.

Genitourological Disorders

Genitourological disorders comprise benign and malign disorders of theorgans constituting the genitourological system of female and male,renal diseases like acute or chronic renal failure, immunologicallymediated renal diseases like renal transplant rejection, lupusnephritis, immune complex renal diseases, glomerulopathies, nephritis,toxic nephropathy, obstructive uropathies like benign prostatichyperplasia (BPH), neurogenic bladder syndrome, urinary incontinencelike urge-, stress-, or overflow incontinence, pelvic pain, and erectiledysfunction.

The FPRL1 receptor is highly expressed in different genito-urologicaltissues as prostate and placenta. The expression in the above mentionedtissues suggests an association between FPRL1 and genito-urologicaldiseases. FPRL1 can be regulated to treat disorders of thegenito-urological system. Genito-urological disorders which may betreated include but are not limited to benign prostatic hyperplasia(BPH), urinary incontinence and erectile dysfunction.

Inflammatory Diseases

Inflammatory diseases comprise diseases triggered by cellular ornon-cellular mediators of the immune system or tissues causing theinflammation of body tissues and subsequently producing an acute orchronic inflammatory condition. Examples for such inflammatory diseasesare hypersensitivity reactions of type I-IV, for example but not limitedto hypersensitivity diseases of the lung including asthma, atopicdiseases, allergic rhinitis or conjunctivitis, angioedema of the lids,hereditary angioedema, antireceptor hypersensitivity reactions andautoimmune diseases, Hashimoto's thyroiditis, systemic lupuserythematosus, Goodpasture's syndrome, pemphigus, myasthenia gravis,Grave's and Raynaud's disease, type B insulin-resistant diabetes,rheumatoid arthritis, psoriasis, Crohn's disease, scleroderma, mixedconnective tissue disease, polymyositis, sarcoidosis,glomerulonephritis, acute or chronic host versus graft reactions.

The FPRL1 receptor is highly expressed in different tissues of theimmune system and tissues responsive to components of the immune systemas well as tissues responsive to mediators of inflammation. Theexpression in the above mentioned tissues suggests an associationbetween FPRL1 and inflammatory diseases. FPRL1 can be regulated to treatinflammatory diseases and FPRL1 can be measured in order to diagnosesuch diseases.

Applications

The present invention provides for both prophylactic and therapeuticmethods for hematological diseases, cardiovascular diseases, disordersof the peripheral and central nervous system, respiratory diseases likeCOPD, asthma, genito-urological disorders and inflammation diseases.

The regulatory method of the invention involves contacting a cell withan agent that modulates one or more of the activities of FPRL1. An agentthat modulates activity can be an agent as described herein, such as anucleic acid or a protein, a naturally-occurring cognate ligand of thepolypeptide, a peptide, a peptidomimetic, or any small molecule. In oneembodiment, the agent stimulates one or more of the biologicalactivities of FPRL1. Examples of such stimulatory agents include theactive FPRL1 and nucleic acid molecules encoding a portion of FPRL1. Inanother embodiment, the agent inhibits one or more of the biologicalactivities of FPRL1. Examples of such inhibitory agents includeantisense nucleic acid molecules and antibodies. These regulatorymethods can be performed in vitro (e.g., by culturing the cell with theagent) or, alternatively, in vivo (e.g, by administering the agent to asubject). As such, the present invention provides methods of treating anindividual afflicted with a disease or disorder characterized byunwanted expression or activity of FPRL1 or a protein in the FPRL1signaling pathway. In one embodiment, the method involves administeringan agent like any agent identified or being identifiable by a screeningassay as described herein, or combination of such agents that modulatesay upregulate or downregulate the expression or activity of FPRL1 or ofany protein in the FPRL1 signaling pathway. In another embodiment, themethod involves administering a regulator of FPRL1 as therapy tocompensate for reduced or undesirably low expression or activity ofFPRL1 or a protein in the FPRL1 signaling pathway.

Stimulation of activity or expression of FPRL1 is desirable insituations in which activity or expression is abnormally low and inwhich increased activity is likely to have a beneficial effect.Conversely, inhibition of activity or expression of FPRL1 is desirablein situations in which activity or expression of FPRL1 is abnormallyhigh and in which decreasing its activity is likely to have a beneficialeffect.

This invention is further illustrated by the following examples whichshould not be construed as limiting. The contents of all references,patents and published patent applications cited throughout thisapplication are hereby incorporated by reference.

Pharmaceutical Compositions

This invention further pertains to novel agents identified by theabove-described screening assays and uses thereof for treatments asdescribed herein.

The nucleic acid molecules, polypeptides, and antibodies (also referredto herein as “active compounds”) of the invention can be incorporatedinto pharmaceutical compositions suitable for administration. Suchcompositions typically comprise the nucleic acid molecule, protein, orantibody and a pharmaceutically acceptable carrier. As used herein thelanguage “pharmaceutically acceptable carrier” is intended to includeany and all solvents, dispersion media, coatings, antibacterial andantifungal agents, isotonic and absorption delaying agents, and thelike, compatible with pharmaceutical administration. The use of suchmedia and agents for pharmaceutically active substances is well known inthe art. Except insofar as any conventional media or agent isincompatible with the active compound, use thereof in the compositionsis contemplated. Supplementary active compounds can also be incorporatedinto the compositions.

The invention includes pharmaceutical compositions comprising aregulator of FPRL1 expression or activity (and/or a regulator of theactivity or expression of a protein in the FPRL1 signaling pathway) aswell as methods for preparing such compositions by combining one or moresuch regulators and a pharmaceutically acceptable carrier. Also withinthe invention are pharmaceutical compositions comprising a regulatoridentified using the screening assays of the invention packaged withinstructions for use. For regulators that are antagonists of FPRL1activity or which reduce FPRL1 expression, the instructions wouldspecify use of the pharmaceutical composition for treatment ofhematological and cardiovascular diseases, disorders of the peripheraland central nervous system, COPD, asthma, genito-urological disordersand inflammation diseases. For regulators that are agonists of FPRL1activity or increase FPRL1 expression, the instructions would specifyuse of the pharmaceutical composition for treatment of hematological andcardiovascular diseases, disorders of the peripheral and central nervoussystem, COPD, asthma, genito-urological disorders and inflammationdiseases.

An antagonist of FPRL1 may be produced using methods which are generallyknown in the art. In particular, purified FPRL1 may be used to produceantibodies or to screen libraries of pharmaceutical agents to identifythose which specifically bind FPRL1. Antibodies to FPRL1 may also begenerated using methods that are well known in the art. Such antibodiesmay include, but are not limited to, polyclonal, monoclonal, chimeric,single chain antibodies, Fab fragments, and fragments produced by a Fabexpression library. Neutralizing antibodies like those which inhibitdimer formation are especially preferred for therapeutic use.

In another embodiment of the invention, the polynucleotides encodingFPRL1, or any fragment or complement thereof, may be used fortherapeutic purposes. In one aspect, the complement of thepolynucleotide encoding FPRL1 may be used in situations in which itwould be desirable to block the transcription of the mRNA. Inparticular, cells may be transformed with sequences complementary topolynucleotides encoding FPRL1. Thus, complementary molecules orfragments may be used to modulate FPRL1 activity, or to achieveregulation of gene function. Such technology is now well known in theart, and sense or antisense oligonucleotides or larger fragments can bedesigned from various locations along the coding or control regions ofsequences encoding FPRL1.

Expression vectors derived from retroviruses, adenoviruses, or herpes orvaccinia viruses, or from various bacterial plasmids, may be used fordelivery of nucleotide sequences to the targeted organ, tissue, or cellpopulation. Methods which are well known to those skilled in the art canbe used to construct vectors which will express nucleic acid sequencecomplementary to the polynucleotides of the gene encoding FPRL1. Thesetechniques are described, for example, in [Scott and Smith (1990)Science 249:386-390].

Any of the therapeutic methods described above may be applied to anysubject in need of such therapy, including, for example, mammals such asdogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administrationof a pharmaceutical composition containing FPRL1 in conjunction with apharmaceutically acceptable carrier, for any of the therapeutic effectsdiscussed above. Such pharmaceutical compositions may consist of FPRL1,antibodies to FPRL1, and mimetics, agonists, antagonists, or inhibitorsof FPRL1. The compositions may be administered alone or in combinationwith at least one other agent, such as a stabilizing compound, which maybe administered in any sterile, bio-compatible pharmaceutical carrierincluding, but not limited to, saline, buffered saline, dextrose, andwater. The compositions may be administered to a patient alone, or incombination with other agents, drugs or hormones.

A pharmaceutical composition of the invention is formulated to becompatible with its intended route of administration. Examples of routesof administration include parenteral, e.g., intravenous, intradermal,subcutaneous, oral (e.g., inhalation), transdermal (topical),transmucosal, and rectal adrinistration. Solutions or suspensions usedfor parenteral, intradermal, or subcutaneous application can include thefollowing components: a sterile diluent such as water for injection,saline solution, fixed oils, polyethylene glycols, glycerine, propyleneglycol or other synthetic solvents; antibacterial agents such as benzylalcohol or methyl parabens; antioxidants such as ascorbic acid or sodiumbisulfite; chelating agents such as ethylenediamine-tetraacetic acid;buffers such as acetates, citrates or phosphates and agents for theadjustment of tonicity such as sodium chloride or dextrose. pH can beadjusted with acids or bases, such as hydrochloric acid or sodiumhydroxide. The parenteral preparation can be enclosed in ampoules,disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterileaqueous solutions (where water soluble) or dispersions and sterilepowders for the extemporaneous preparation of sterile injectablesolutions or dispersions. For intravenous administration, suitablecarriers include physiological saline, bacteriostatic water, CremophorEM™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In allcases, the composition must be sterile and should be fluid to the extentthat easy syringability exists. It must be stable under the conditionsof manufacture and storage and must be preserved against thecontaminating action of microorganisms such as bacteria and fungi. Thecarrier can be a solvent or dispersion medium containing, for example,water, ethanol, a pharmaceutically acceptable polyol like glycerol,propylene glycol, liquid polyetheylene glycol, and suitable mixturesthereof. The proper fluidity can be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersion and by the use of surfactants.Prevention of the action of microorganisms can be achieved by variousantibacterial and antifingal agents, for example, parabens,chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In manycases, it will be preferable to include isotonic agents, for example,sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in thecomposition. Prolonged absorption of the injectable compositions can bebrought about by including in the composition an agent which delaysabsorption, for example, aluminum monostearate and gelatin. Sterileinjectable solutions can be prepared by incorporating the activecompound (e.g., a polypeptide or antibody) in the required amount in anappropriate solvent with one or a combination of ingredients enumeratedabove, as required, followed by filtered sterilization. Generally,dispersions are prepared by incorporating the active compound into asterile vehicle which contains a basic dispersion medium and therequired other ingredients from those enumerated above. In the case ofsterile powders for the preparation of sterile injectable solutions, thepreferred methods of preparation are vacuum drying and freeze-dryingwhich yields a powder of the active ingredient plus any additionaldesired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an ediblecarrier. They can be enclosed in gelatin capsules or compressed intotablets. For the purpose of oral therapeutic administration, the activecompound can be incorporated with excipients and used in the form oftablets, troches, or capsules. Oral compositions can also be preparedusing a fluid carrier for use as a mouthwash, wherein the compound inthe fluid carrier is applied orally and swished and expectorated orswallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materialscan be included as part of the composition. The tablets, pills,capsules, troches and the like can contain any of the followingingredients, or compounds of a similar nature: a binder such asmicrocrystalline cellulose, gum tragacanth or gelatin; an excipient suchas starch or lactose, a disintegrating agent such as alginic acid,Primogel, or corn starch; a lubricant such as magnesium stearate orsterotes; a glidant such as colloidal silicon dioxide; a sweeteningagent such as sucrose or saccharin; or a flavoring agent such aspeppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in theform of an aerosol spray from a pressurized container or disperiserwhich contains a suitable propellant, e.g., a gas such as carbondioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermalmeans. For transmucosal or transdermal administration, penetrantsappropriate to the barrier to be permeated are used in the formulation.Such penetrants are generally known in the art, and include, forexample, for transmucosal administration, detergents, bile salts, andfusidic acid derivatives. Transmucosal administration can beaccomplished through the use of nasal sprays or suppositories. Fortransdermal administration, the active compounds are formulated intoointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g.,with conventional suppository bases such as cocoa butter and otherglycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers thatwill protect the compound against rapid elimination from the body, suchas a controlled release formulation, including implants andmicroencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid.Methods for preparation of such formulations will be apparent to thoseskilled in the art. The materials can also be obtained commercially fromAlza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions(including liposomes targeted to infected cells with monoclonalantibodies to viral antigens) can also be used as pharmaceuticallyacceptable carriers. These can be prepared according to methods known tothose skilled in the art, for example, as described in U.S. Pat. No.4,522,811.

It is especially advantageous to formulate oral or parenteralcompositions in dosage unit form for ease of administration anduniformity of dosage. Dosage unit form as used herein refers tophysically discrete units suited as unitary dosages for the subject tobe treated; each unit containing a predetermined quantity of activecompound calculated to produce the desired therapeutic effect inassociation with the required pharmaceutical carrier. The specificationfor the dosage unit forms of the invention are dictated by and directlydependent on the unique characteristics of the active compound and theparticular therapeutic effect to be achieved, and the limitationsinherent in the art of compounding such an active compound for thetreatment of individuals.

The pharmaceutical compositions can be included in a container, pack, ordispenser together with instructions for administration. Forpharmaceutical compositions which include an antagonist of FPRL1activity, a compound which reduces expression of FPRL1, or a compoundwhich reduces expression or activity of a protein in the FPRL1 signalingpathway or any combination thereof, the instructions for administrationwill specify use of the composition for hematological and cardiovasculardiseases, disorders of the peripheral and central nervous system, COPD,asthma, genito-urological disorders and inflammation diseases. Forpharmaceutical compositions which include an agonist of FPRL1 activity,a compound which increases expression of FPRL1, or a compound whichincreases expression or activity of a protein in the FPRL1 signalingpathway or any combination thereof, the instructions for administrationwill specify use of the composition for hematological and cardiovasculardiseases, disorders of the peripheral and central nervous system, COPD,asthma, genito-urological disorders and inflammation diseases.

Diagnostics

In another embodiment, antibodies which specifically bind FPRL1 may beused for the diagnosis of disorders characterized by the expression ofFPRL1, or in assays to monitor patients being treated with FPRL1 oragonists, antagonists, and inhibitors of FPRL1. Antibodies useful fordiagnostic purposes may be prepared in the same manner as thosedescribed above for therapeutics. Diagnostic assays for FPRL1 includemethods which utilize the antibody and a label to detect FPRL1 in humanbody fluids or in extracts of cells or tissues. The antibodies may beused with or without modification, and may be labeled by covalent ornon-covalent joining with a reporter molecule. A wide variety ofreporter molecules, several of which are described above, are known inthe art and may be used.

A variety of protocols for measuring FPRL1, including ELISAs, RIAs, andFACS, are known in the art and provide a basis for diagnosing altered orabnormal levels of FPRL1 expression. Normal or standard values for FPRL1expression are established by combining body fluids or cell extractstaken from normal mammalian subjects, preferably human, with antibody toFPRL1 under conditions suitable for complex formation The amount ofstandard complex formation may be quantified by various methods,preferably by photometric means. Quantities of FPRL1 expressed insubject samples from biopsied tissues are compared with the standardvalues. Deviation between standard and subject values establishes theparameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encodingFPRL1 may be used for diagnostic purposes. The polynucleotides which maybe used include oligonucleotide sequences, complementary RNA and DNAmolecules, and PNAs. The polynucleotides may be used to detect andquantitate gene expression in biopsied tissues in which expression ofFPRL1 may be correlated with disease. The diagnostic assay may be usedto distinguish between absence, presence, and excess expression ofFPRL1, and to monitor regulation of FPRL1 levels during therapeuticintervention.

Polynucleotide sequences encoding FPRL1 may be used for the diagnosis ofhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases like COPD,asthma, genito-urological disorders and inflammation diseases associatedwith expression of FPRL1. The polynucleotide sequences encoding FPRL1may be used in Southern, Northern, or dot-blot analysis, or othermembrane-based technologies; in PCR technologies; in dipstick, pin, andELISA assays; and in microarrays utilizing fluids or tissues frompatient biopsies to detect altered FPRL1 expression. Such qualitative orquantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding FPRL1 may beuseful in assays that detect the presence of associated disorders,particularly those mentioned above. The nucleotide sequences encodingFPRL1 may be labelled by standard methods and added to a fluid or tissuesample from a patient under conditions suitable for the formation ofhybridization complexes. After a suitable incubation period, the sampleis washed and the signal is quantitated and compared with a standardvalue. If the amount of signal in the patient sample is significantlyaltered from that of a comparable control sample, the nucleotidesequences have hybridized with nucleotide sequences in the sample, andthe presence of altered levels of nucleotide sequences encoding FPRL1 inthe sample indicates the presence of the associated disorder. Suchassays may also be used to evaluate the efficacy of a particulartherapeutic treatment regimen in animal studies, in clinical trials, orin monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of hematological diseases,cardiovascular diseases, disorders of the peripheral and central nervoussystem, respiratory diseases like COPD, asthma, genito-urologicaldisorders and inflammation diseases associated with expression of FPRL1,a normal or standard profile for expression is established. This may beaccomplished by combining body fluids or cell extracts taken from normalsubjects, either animal or human, with a sequence, or a fragmentthereof, encoding FPRL1, under conditions suitable for hybridization oramplification. Standard hybridization may be quantified by comparing thevalues obtained from normal subjects with values from an experiment inwhich a known amount of a substantially purified polynucleotide is used.Standard values obtained from normal samples may be compared with valuesobtained from samples from patients who are symptomatic for a disorder.Deviation from standard values is used to establish the presence of adisorder.

Another technique for drug screening which may be used provides for highthrough-put screening of compounds having suitable binding affinity tothe protein of interest as described in published PCT applicationWO84/03564. In this method, large numbers of different small testcompounds are synthesized on a solid substrate, such as plastic pins orsome other surface. The test compounds are reacted with FPRL1, orfragments thereof, and washed. Bound FPRL1 is then detected by methodswell known in the art. Purified FPRL1 can also be coated directly ontoplates for use in the aforementioned drug screening techniques.Alternatively, non-neutralizing antibodies can be used to capture thepeptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays inwhich neutralizing antibodies capable of binding FPRL1 specificallycompete with a test compound for binding FPRL1. In this manner,antibodies can be used to detect the presence of any peptide whichshares one or more antigenic determinants with FPRL1.

G-protein coupled receptors are ubiquitous in the mammalian host and areresponsible for many biological functions, including many pathologies.Accordingly, it is desirable to find compounds and drugs which stimulatea G-protein coupled receptor on the one hand and which can inhibit thefunction of a G-protein coupled receptor on the other hand. For example,compounds which activate the G-protein coupled receptor may be employedfor therapeutic purposes, such as the treatment of asthma, Parkinson'sdisease, acute heart failure, urinary retention, and osteoporosis. Inparticular, compounds which activate the receptors of the presentinvention are useful in treating various cardiovascular ailments such ascaused by the lack of pulmonary blood flow or hypertension. In additionthese compounds may also be used in treating various physiologicaldisorders relating to abnormal control of fluid and electrolytehomeostasis and in diseases associated with abnormal angiotensin-inducedaldosterone secretion.

In general, compounds which inhibit activation of the G-protein coupledreceptor may be employed for a variety of therapeutic purposes, forexample, for the treatment of hypotension and/or hypertension, anginapecton's, myocardial infarction, ulcers, asthma, allergies, benignprostatic hypertrophy, and psychotic and neurological disordersincluding schizophrenia, manic excitement, depression, delirium,dementia or severe mental retardation, dyskinesias, such as Huntington'sdisease or Tourett's syndrome, among others. Compounds which inhibitG-protein coupled receptors have also been useful in reversingendogenous anorexia and in the control of bulimia.

Determination of a Therapeutically Effective Dose

The determination of a therapeutically effective dose is well within thecapability of those skilled in the art. A therapeutically effective doserefers to that amount of active ingredient which increases or decreasesFPRL1 activity relative to FPRL1 activity which occurs in the absence ofthe therapeutically effective dose. For any compound, thetherapeutically effective dose can be estimated initially either in cellculture assays or in animal models, usually mice, rabbits, dogs, orpigs. The animal model also can be used to determine the appropriateconcentration range and route of administration. Such information canthen be used to determine useful doses and routes for administration inhumans.

Therapeutic efficacy and toxicity, e.g., ED₅₀ (the dose therapeuticallyeffective in 50% of the population) and LD₅₀ (the dose lethal to 50% ofthe population), can be determined by standard pharmaceutical proceduresin cell cultures or experimental animals. The dose ratio of toxic totherapeutic effects is the therapeutic index, and it can be expressed asthe ratio, LD₅₀/ED₅₀. Pharmaceutical compositions which exhibit largetherapeutic indices are preferred. The data obtained from cell cultureassays and animal studies is used in formulating a range of dosage forhuman use. The dosage contained in such compositions is preferablywithin a range of circulating concentrations that include the ED₅₀ withlittle or no toxicity. The dosage varies within this range dependingupon the dosage form-employed, sensitivity of the patient, and the routeof administration. The exact dosage will be determined by thepractitioner, in light of factors related to the subject that requirestreatment. Dosage and administration are adjusted to provide sufficientlevels of the active ingredient or to maintain the desired effect.Factors which can be taken into account include the severity of thedisease state, general health of the subject, age, weight, and gender ofthe subject, diet, time and frequency of administration, drugcombination(s), reaction sensitivities, and tolerance/response totherapy. Long-acting pharmaceutical compositions can be administeredevery 3 to 4 days, every week, or once every two weeks depending on thehalf-life and clearance rate of the particular formulation.

Normal dosage amounts can vary from 0.1 micrograms to 100,000micrograms, up to a total dose of about 1 g, depending upon the route ofadministration. Guidance as to particular dosages and methods ofdelivery is provided in the literature and generally available topractitioners in the art. Those skilled in the art will employ differentformulations for nucleotides than for proteins or their inhibitors.Similarly, delivery of polynucleotides or polypeptides will be specificto particular cells, conditions, locations, etc. If the reagent is asingle-chain antibody, polynucleotides encoding the antibody can beconstructed and introduced into a cell either ex vivo or in vivo usingwell-established techniques including, but not limited to,transferrin-polycation-mediated DNA transfer, transfection with naked orencapsulated nucleic acids, liposome-mediated cellular fusion,intracellular transportation of DNA-coated latex beads, protoplastfusion, viral infection, electroporation, “gene gun”, and DEAE- orcalcium phosphate-mediated transfection.

If the expression product is mRNA, the reagent is preferably anantisense oligonucleotide or a ribozyme. Polynucleotides which expressantisense oligonucleotides or ribozymes can be introduced into cells bya variety of methods, as described above. Preferably, a reagent reducesexpression of FPRL1 gene or the activity of FPRL1 by at least about 10,preferably about 50, more preferably about 75, 90, or 100% relative tothe absence of the reagent. The effectiveness of the mechanism chosen todecrease the level of expression of FPRL1 gene or the activity of FPRL1can be assessed using methods well known in the art, such ashybridization of nucleotide probes to FPRL1-specific mRNA, quantitativeRT-PCR, immunologic detection of FPRL1, or measurement of FPRL1activity.

In any of the embodiments described above any of the pharmaceuticalcompositions of the invention can be administered in combination withother appropriate therapeutic agents. Selection of the appropriateagents for use in combination therapy can be made by one of ordinaryskill in the art, according to conventional pharmaceutical principles.The combination of therapeutic agents can act synergistically to effectthe treatment or prevention of the various disorders described above.Using this approach, one may be able to achieve therapeutic efficacywith lower dosages of each agent, thus reducing the potential foradverse side effects. Any of the therapeutic methods described above canbe applied to any subject in need of such therapy, including, forexample, mammals such as dogs, cats, cows, horses, rabbits, monkeys, andmost preferably, humans.

Nucleic acid molecules of the invention are those nucleic acid moleculeswhich are contained in a group of nucleic acid molecules consisting of(i) nucleic acid molecules encoding a polypeptide comprising the aminoacid sequence of SEQ ID NO: 2, (ii) nucleic acid molecules comprisingthe sequence of SEQ ID NO: 1, (iii) nucleic acid molecules having thesequence of SEQ ID NO: 1, (iv) nucleic acid molecules the complementarystrand of which hybridizes under stringent conditions to a nucleic acidmolecule of (i), (ii), or (iii); and (v) nucleic acid molecules thesequence of which differs from the sequence of a nucleic acid moleculeof (iii) due to the degeneracy of the genetic code, wherein thepolypeptide encoded by said nucleic acid molecule has FPRL1 activity.

Polypeptides of the invention are those polypeptides which are containedin a group of polypeptides consisting of (i) polypeptides having thesequence of SEQ ID NO: 2, (ii) polypeptides comprising the sequence ofSEQ ID NO: 2, (iii) polypeptides encoded by nucleic acid molecules ofthe invention and (iv) polypeptides which show at least 99%, 98%, 95%,90%, or 80% homology with a polypeptide of (i), (ii), or (iii), whereinsaid purified polypeptide has FPRL1 activity.

An object of the invention is a method of screening for therapeuticagents useful in the treatment of a disease comprised in a group ofdiseases consisting of hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases like COPD, asthma, genito-urological disorders and inflammationdiseases in a mammal comprising the steps of (i) contacting a testcompound with a FPRL1 polypeptide, (ii) detect binding of said testcompound to said FPRL1 polypeptide. E.g., compounds that bind to theFPRL1 polypeptide are identified potential therapeutic agents for such adisease.

Another object of the invention is a method of screening for therapeuticagents useful in the treatment of a disease comprised in a group ofdiseases consisting of hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases like COPD, asthma, genito-urological disorders and inflammationdiseases in a mammal comprising the steps of (i) determining theactivity of a FPRL1 polypeptide at a certain concentration of a testcompound or in the absence of said test compound, (ii) determining theactivity of said polypeptide at a different concentration of said testcompound. E.g., compounds that lead to a difference in the activity ofthe FPRL1 polypeptide in (i) and (ii) are identified potentialtherapeutic agents for such a disease.

Another object of the invention is a method of screening for therapeuticagents useful in the treatment of a disease comprised in a group ofdiseases consisting of hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases like COPD, asthma, genito-urological disorders and inflammationdiseases in a mammal comprising the steps of (i) determining theactivity of a FPRL1 polypeptide at a certain concentration of a testcompound, (ii) determining the activity of a FPRL1 polypeptide at thepresence of a compound known to be a regulator of a FPRL1 polypeptide.E.g.; compounds that show similar effects on the activity of the FPRL1polypeptide in (i) as compared to compounds used in (ii) are identifiedpotential therapeutic agents for such a disease.

Other objects of the invention are methods of the above, wherein thestep of contacting is in or at the surface of a cell.

Other objects of the invention are methods of the above, wherein thecell is in vitro.

Other objects of the invention are methods of the above, wherein thestep of contacting is in a cell-free system.

Other objects of the invention are methods of the above, wherein thepolypeptide is coupled to a detectable label.

Other objects of the invention are methods of the above, wherein thecompound is coupled to a detectable label.

Other objects of the invention are methods of the above, wherein thetest compound displaces a ligand which is first bound to thepolypeptide.

Other objects of the invention are methods of the above, wherein thepolypeptide is attached to a solid support.

Other objects of the invention are methods of the above, wherein thecompound is attached to a solid support.

Another object of the invention is a method of screening for therapeuticagents useful in the treatment of a disease comprised in a group ofdiseases consisting of hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases like COPD, asthma, genito-urological disorders and inflammationdiseases in a mammal comprising the steps of (i) contacting a testcompound with a FPRL1 polynucleotide, (ii) detect binding of said testcompound to said FPRL1 polynucleotide. Compounds that, e.g., bind to theFPRL1 polynucleotide are potential therapeutic agents for the treatmentof such diseases.

Another object of the invention is the method of the above, wherein thenucleic acid molecule is RNA.

Another object of the invention is a method of the above, wherein thecontacting step is in or at the surface of a cell.

Another object of the invention is a method of the above, wherein thecontacting step is in a cell-free system.

Another object of the invention is a method of the above, wherein thepolynucleotide is coupled to a detectable label.

Another object of the invention is a method of the above, wherein thetest compound is coupled to a detectable label.

Another object of the invention is a method of diagnosing a diseasecomprised in a group of diseases consisting of hematological diseases,cardiovascular diseases, disorders of the peripheral and central nervoussystem, respiratory diseases like COPD, asthma, genito-urologicaldisorders and inflammation diseases in a mammal comprising the steps of(i) determining the amount of a FPRL1 polynucleotide in a sample takenfrom said mammal, (ii) determining the amount of FPRL1 polynucleotide inhealthy and/or diseased mammal. A disease is diagnosed, e.g., if thereis a substantial similarity in the amount of FPRL1 polynucleotide insaid test mammal as compared to a diseased mammal.

Another object of the invention is a pharmaceutical composition for thetreatment of a disease comprised in a group of diseases consisting ofhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases like COPD,asthma, genito-urological disorders and inflammation diseases in amammal comprising a therapeutic agent which binds to a FPRL1polypeptide.

Another object of the invention is a pharmaceutical composition for thetreatment of a disease comprised in a group of diseases consisting ofhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases like COPD,asthma, genito-urological disorders and inflammation diseases in amammal comprising a therapeutic agent which regulates the activity of aFPRL1 polypeptide.

Another object of the invention is a pharmaceutical composition for thetreatment of a disease comprised in a group of diseases consisting ofhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases like COPD,asthma, genito-urological disorders and inflammation diseases in amammal comprising a therapeutic agent which regulates the activity of aFPRL1 polypeptide, wherein said therapeutic agent is (i) a smallmolecule, (ii) an RNA molecule, (iii) an antisense oligonucleotide, (iv)a polypeptide, (v) an antibody, or (vi) a ribozyme.

Another object of the invention is a pharmaceutical composition for thetreatment of a disease comprised in a group of diseases consisting ofhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases like COPD,asthma, genito-urological disorders and inflammation diseases in amammal comprising a FPRL1 polynucleotide.

Another object of the invention is a pharmaceutical composition for thetreatment of a disease comprised in a group of diseases consisting ofhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases like COPD,asthma, gerito-urological disorders and inflammation diseases in amammal comprising a FPRL1 polypeptide.

Another object of the invention is the use of regulators of a FPRL1 forthe preparation of a pharmaceutical composition for the treatment of adisease comprised in a group of diseases consisting of hematologicaldiseases, cardiovascular diseases, disorders of the peripheral andcentral nervous system, respiratory diseases like COPD, asthma,genito-urological disorders and inflammation diseases in a mammal.

Another object of the invention is a method for the preparation of apharmaceutical composition useful for the treatment of a diseasecomprised in a group of diseases consisting of hematological diseases,cardiovascular diseases, disorders of the peripheral and central nervoussystem, respiratory diseases like COPD, asthma, genito-urologicaldisorders and inflammation diseases in a mammal comprising the steps of(i) identifying a regulator of FPRL1, (ii) determining whether saidregulator ameliorates the symptoms of a disease comprised in a group ofdiseases consisting of hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases like COPD, asthma, genito-urological disorders and inflammationdiseases in a mammal; and (iii) combining of said regulator with anacceptable pharmaceutical carrier.

Another object of the invention is the use of a regulator of FPRL1 forthe regulation of FPRL1 activity in a mammal having a disease comprisedin a group of diseases consisting of hematological diseases,cardiovascular diseases, disorders of the peripheral and central nervoussystem, respiratory diseases like COPD, asthma, genito-urologicaldisorders and inflammation diseases.

The examples below are provided to illustrate the subject invention.These examples are provided by way of illustration and are not includedfor the purpose of limiting the invention.

EXAMPLES Example 1 Search for Homologous Sequences in Public SequenceData Bases

The degree of homology can readily be calculated by known methods.Preferred methods to determine homology are designed to give the largestmatch between the sequences tested. Methods to determine homology arecodified in publicly available computer programs such as BestFit,BLASTP, BLASTN, and FASTA. The BLAST programs are publicly availablefrom NCBI and other sources in the internet.

For FPRL1 the following hits to known sequences were identified by usingthe BLAST algorithm [Altschul S F, Madden T L, Schaffer A A, Zhang J,Zhang Z, Miller W, Lipman D J; Nucleic Acids Res 1997 Sep. 1; 25(17):3389-402] and the following set of parameters: matrix=BLOSUM62 and lowcomplexity filter. The following databases were searched: NCBI(non-redundant database) and DERWENT patent database (Geneseq).

The following hits were found:

-   >ref|NM_(—)001462.1| Homo sapiens formyl peptide receptor-like 1    (FPRL1), mRNA, Length=2631, Score=5216 bits (2631), Expect=0.0,    Identities=2631/2631 (100%)-   >gb|M84562.1|HUMFPRL1A Human formyl peptide receptor-like receptor    (FPRL1) mRNA, complete cds, Length=2631, Score=5216 bits (2631),    Expect=0.0, Identities=2631/2631 (100%)-   >ref|XM_(—)009374.2| Homo sapiens similar to formyl peptide    receptor-like 1 (H. sapiens) (LOC125882), mRNA, Length=1876,    Score=3719 bits (1876), Expect=0.0, Identities=1876/1876 (100%)-   >gb|AC018755.3|AC018755 Homo sapiens chromosome 19, BAC BC330783    (CIT-HSPC_(—)470E3), complete sequence, Length=229155, Score=3719    bits (1876), Expect=0.0, Identities=1876/1876 (100%)-   >dbj|D10922.1|HUMHM63 Human mRNA for FMLP-related receptor (HM63),    Length=1910, Score=3699 bits (1866), Expect=0.0,    Identities=1872/1874 (99%)-   >emb|X63819.1|HSLIPA4R H. sapiens mRNA for Lipoxin A4 receptor,    Length=1776, Score=3491 bits (1761), Expect=0.0,    Identities=1761/1761 (100%)-   >ref|XM_(—)031082.1| Homo sapiens formyl peptide receptor-like 1    (FPRL1), mRNA, Length=1650, Score=3223 bits (1626), Expect=0.0,    Identities=1626/1626 (100%)-   >gb|M88107.1|HUMPFPR2A Human formyl peptide receptor (FPR2) mRNA,    complete cds, Length=1650, Score=3186 bits (1607), Expect=0.0,    Identities=1624/1627 (99%), Gaps=2/1627 (0%)-   >gb|U81501.1|HSU81501 Human lipoxin A4 receptor mRNA, complete cds,    Length=1090, Score=2161 bits (1090), Expect=0.0,    Identities=1090/1090 (1006)-   >gb|AF054013.1|AF054013 Homo sapiens lipoxin A4 receptor mRNA,    complete cds, Length=1056, Score=2093 bits (1056), Expect=0.0,    Identities=1056/1056 (100%)-   >gb|M76672.1|HUMFMLPX Human FMLP-related receptor II (FMLP R II)    mRNA, complete cds, Length=1058, Score=2089 bits (1054), Expect=0.0,    Identities=1057/1058 (99%)-   >emb|AX280877.1|AX280877 Sequence 500 from patent application    WO0177172, Length=1056, Score=2078 bits (1048), Expect=0.0,    Identities=1054/1056 (99%)-   >emb|X97738.1|GGFPRFPRL G.gorilla DNA for low affinity N-formyl    peptide receptor, Length=1044, Score=2014 bits (1016), Expect=0.0,    Identities=1037/1044 (99%)

Example 2 Expression Profiling Total cellular RNA was isolated fromcells by one of two standard methods: 1) guanidine isothiocyanate/Cesiumchloride density gradient centrifugation [Kellogg, (1990)]; or with theTri-Reagent protocol according to the manufacture's specifications(Molecular Research Center, Inc., Cincinatti, Ohio). Total RNA preparedby the Tri-reagent protocol was treated with DNAse I to remove genomicDNA contamination.

For relative quantitation of the mRNA distribution of FPRL1, total RNAfrom each cell or tissue source was first reverse transcribed. 85 μg oftotal RNA was reverse transcribed using 1 μmole random hexamer primers,0.5 mM each of DATP, dCTP, dGTP and dTTP (Qiagen, Hilden, Germany), 3000U RnaseQut (Invitrogen, Groningen, Netherlands) in a final volume of 680μl. The first strand synthesis buffer and Omniscript reversetranscriptase (2 u/μl) were from (Qiagen, Hilden, Germany). The reactionwas incubated at 37° C. for 90 minutes and cooled on ice. The volume wasadjusted to 6800 μl with water, yielding a final concentration of 12.5ng/μl of starting RNA

For relative quantitation of the distribution of FPRL1 mRNA in cells andtissues the Perkin Elmer ABI Prism RTM. 7700 Sequence Detection systemor Biorad iCycler was used according to the manufacturer'sspecifications and protocols. PCR reactions were set up to quantitateFPRL1 and the housekeeping genes HPRT (hypoxanthinephosphoribosyltransferase), GAPDH (glyceraldehyde-3-phosphatedehydrogenase), β-actin, and others. Forward and reverse primers andprobes for FPRL1 were designed using the Perkin Elmer ABI PrimerExpress™ software and were synthesized by TibMolBiol (Berlin, Germany).The FPRL1 forward primer sequence was: Primer1 (SEQ ID NO: 3). The FPRL1reverse primer sequence was Primer2 (SEQ ID NO: 5). Probe1 (SEQ ID NO:4), labelled with FAM (carboxyfluorescein succinimidyl ester) as thereporter dye and TAMPA (carboxytetramethylrhodamine) as the quencher, isused as a probe for FPRL1. The following reagents were prepared in atotal of 25 μl: 1×TaqMan buffer A, 5.5 mM MgCl₂, 200 nM of dATP, dCTP,dGTP, and DUTP, 0.025 U/μl ApliTaq Gold™, 0.01 U/μl AmpErase and Probe1(SEQ ID NO: 4), FPRL1 forward and reverse primers each at 200 nM, 200 nMFPRL1 FAM/TAMRA-labelled probe, and 5 μl of template cDNA. Thermalcycling parameters were 2 min at 50° C., followed by 10 min at 95° C.,followed by 40 cycles of melting at 95° C. for 15 sec andannealing/extending at 60° C. for 1 min.

Calculation of Corrected CT Values

The CT (threshold cycle) value is calculated as described in the“Quantitative determination of nucleic acids” section. The CF-value(factor for threshold cycle correction) is calculated as follows:

-   1. PCR reactions were set up to quantitate the housekeeping genes    (HKG) for each cDNA sample.-   2. CT_(HKG)-values (threshold cycle for housekeeping gene) were    calculated as described in the “Quantitative determination of    nucleic acids” section.-   3. CT_(HKG)-mean values (CT mean value of all HKG tested on one    cDNAs) of all HKG for each cDNA are calculated (n=number of HKG):    -   CT_(HKG-n)-mean value=(CT_(HKG1)-value+CT_(HKG2)-value+ . . .        +CT_(HKG-n)-value)/n-   4. CT_(pannel) mean value (CT mean value of all HKG in all tested    cDNAs)=(CT_(HKG1)-mean value+CT_(HKG2)-mean value+ . . .    +CT_(HKG-y)-mean value)/y (y=number of cDNAs)-   5. CF_(cDNA-n) (correction factor for cDNA n)=CT_(pannel)-mean    value−CT_(HKG-n)-mean value-   6. CT_(cDNA-n) (CT value of the tested gene for the cDNA    n)+CF_(cDNA-n) (correction factor for cDNA n)=CT_(cor-cDNA-n)    (corrected CT value for a gene on cDNA n)    Calculation of Relative Expression-   Definition: highest CT_(cor-cDNA-n)≠40 is defined as CT_(cor-cDNA)    [high] Relative Expression=2^((CTcor-cDNA[high]−CTcor-cDNA-n))    Tissues

The expression of FPRL1 was investigated in the following tissues:Coronary smooth muscle cells, brain, testis, pancreas, stomach,cerebellum, trachea, adrenal gland, skeletal muscle, salivary gland,small intestine, prostata, fetal liver, placenta, fetal brain, uterus,mammary gland, heart, spleen, lung, HeLa cells, liver, kidney, thymus,bone marrow, thyroid, colon, bladder, spinal cord, peripheral blood,liver, liver in cirrhosis, pancreas liver cirrhosis, spleen livercirrhosis, total Alzheimer brain, fetal lung, breast tumor, colon tumor,lung tumor, HEK 293 cells, adipose, pericardium, fetal heart, thyroidtumor, MDA MB 231 cells, HEP G2 cells, HUVEC cells, fetal kidney,breast, Jurkat T-cells, Alzheimer brain cortex, cervix, esophagus,thalamus, precentral gyrus, hippocampus, occipital lobe, cerebralpeduncles, postcentral gyrus, temporal lobe, parietal lobe, cerebellum(right), cerebellum (left), tonsilla cerebelli, cerebral meninges, pons,frontal lobe, cerebral cortex, corpus callosum, vermis cerebelli,Alzheimer brain frontal lobe, interventricular septum, heart atrium(right), heart atrium (left), heart ventricle (left), skin, ileumchronic inflammation, erythrocyte, aorta, lung in the state of COPD,aorta sclerotic, prostate in the state of BPH, rectum, retina, penis,penis corpus cavernosum, artery, vein, lymphnode, dorsal root ganglia,thrombocytes.

Expression Profile

The results of the the mRNA-quantification (expression profiling) isshown in Table 1. TABLE 1 Relative expression of FPRL1 in various humantissues. Tissue Relative Expression leukocytes (peripheral blood) 15076esophagus 13216 bone marrow 9878 placenta 7181 spleen 5557 liver livercirrhosis 5113 lung tumor 3616 cerebral meninges 3350 Alzheimer cerebralcortex 3327 liver 3104 liver 3104 breast tumor 2647 Alzheimer brain 2320postcentral gyrus 2272 heart ventricle (left) 2048 HUVEC cells 2020cervix 1746 heart atrium (right) 1652 thymus 1468 lung 1409 heart atrium(left) 1342 colon tumor 1243 breast 1218 trachea 1097 HEK 293 cells 1031cerebellum (left) 1017 Alzheimer brain frontal lobe 1010 small intestine996 stomach 976 coronary artery smooth muscle 923 primary cells adipose879 fetal lung 750 hippocampus 699 thyroid 685 skeletal muscle 564mammary gland 512 uterus 471 occipital lobe 471 cerebral cortex 458thyroid tumor 452 thalamus 428 pons 419 bladder 370 fetal liver 367 HEPG2 cells 362 colon 360 corpus callosum 350 interventricular septum 350fetal kidney 333 pericardium 317 kidney 304 precentral gyrus 296 spleenliver cirrhosis 292 prostata 286 adrenal gland 261 frontal lobe 247heart 241 testis 223 vermis cerebelli 193 spinal cord 185 temporal lobe168 cerebral peduncles 167 tonsilla cerebelli 162 cerebellum (right) 161parietal lobe 159 Jurkat (T-cells) 146 brain 110 MDA MB 231 cells(breast tumor) 98 salivary gland 94 pancreas liver cirrhosis 59 fetalbrain 57 fetal heart 45 cerebellum 22 pancreas 12 HeLa cells (cervixtumor) 1

Example 3 Antisense Analysis

Knowledge of the correct, complete cDNA sequence coding for FPRL1enables its use as a tool for antisense technology in the investigationof gene function. Oligonucleotides, cDNA or genomic fragments comprisingthe antisense strand of a polynucleotide coding for FPRL1 are usedeither in vitro or in vivo to inhibit translation of the mRNA. Suchtechnology is now well known in the art, and antisense molecules can bedesigned at various locations along the nucleotide sequences. Bytreatment of cells or whole test animals with such antisense sequences,the gene of interest is effectively turned off. Frequently, the functionof the gene is ascertained by observing behavior at the intracellular,cellular, tissue or organismal level (e.g., lethality, loss ofdifferentiated function, changes in morphology, etc.).

In addition to using sequences constructed to interrupt transcription ofa particular open reading frame, modifications of gene expression isobtained by designing antisense sequences to intron regions,promoter/enhancer elements, or even to transacting regulatory genes.

Example 4 Expression of FPRL1

Expression of FPRL1 is accomplished by subcloning the cDNAs intoappropriate expression vectors and transfecting the vectors intoexpression hosts such as, e.g., E coli. In a particular case, the vectoris engineered such that it contains a promoter for β-galactosidase,upstream of the cloning site, followed by sequence containing theamino-terminal Methionine and the subsequent seven residues ofβ-galactosidase. Immediately following these eight residues is anengineered bacteriophage promoter useful for artificial priming andtranscription and for providing a number of unique endonucleaserestriction sites for cloning.

Induction of the isolated, transfected bacterial strain withIsopropyl-β-D-thio-galactopyranoside (IPTG) using standard methodsproduces a fusion protein corresponding to the first seven residues ofβ-galactosidase, about 15 residues of “linker”, and the peptide encodedwithin the cDNA. Since cDNA clone inserts are generated by anessentially random process, there is probability of 33% that theincluded cDNA will lie in the correct reading frame for propertranslation. If the cDNA is not in the proper reading frame, it isobtained by deletion or insertion of the appropriate number of basesusing well known methods including in vitro mutagenesis, digestion withexonuclease III or mung bean nuclease, or the inclusion of anoligonucleotide linker of appropriate length.

The FPRL1 cDNA is shuttled into other vectors known to be useful forexpression of proteins in specific hosts. Oligonucleotide primerscontaining cloning sites as well as a segment of DNA (about 25 bases)sufficient to hybridize to stretches at both ends of the target cDNA issynthesized chemically by standard methods. These primers are then usedto amplify the desired gene segment by PCR. The resulting gene segmentis digested with appropriate restriction enzymes under standardconditions and isolated by gel electrophoresis. Alternately, similargene segments are produced by digestion of the cDNA with appropriaterestriction enzymes. Using appropriate primers, segments of codingsequence from more than one gene are ligated together and cloned inappropriate vectors. It is possible to optimize expression byconstruction of such chimeric sequences.

Suitable expression hosts for such chimeric molecules include, but arenot limited to, mammalian cells such as Chinese Hamster Ovary (CHO) andhuman 293 cells, insect cells such as Sf9 cells, yeast cells such asSaccharomyces cerevisiae and bacterial cells such as E. coli. For eachof these cell systems, a useful expression vector also includes anorigin of replication to allow propagation in bacteria, and a selectablemarker such as the β-lactamase antibiotic resistance gene to allowplasmid selection in bacteria. In addition, the vector may include asecond selectable marker such as the neomycin phosphotransferase gene toallow selection in transfected eukaryotic host cells. Vectors for use ineukaryotic expression hosts require RNA processing elements such as 3′polyadenylation sequences if such are not part of the cDNA of interest.

Additionally, the vector contains promoters or enhancers which increasegene expression. Such promoters are host specific and include MMTV,SV40, and metallothionine promoters for CHO cells; trp, lac, tac and T7promoters for bacterial hosts; and alpha factor, alcohol oxidase and PGHpromoters for yeast. Transcription enhancers, such as the rous sarcomavirus enhancer, are used in mammalian host cells. Once homogeneouscultures of recombinant cells are obtained through standard culturemethods, large quantities of recombinantly produced FPRL1 are recoveredfrom the conditioned medium and analyzed using chromatographic methodsknown in the art. For example, FPRL1 can be cloned into the expressionvector pcDNA3, as exemplified herein. This product can be used totransform, for example, HEK293 or COS by methodology standard in theart. Specifically, for example, using Lipofectamine (Gibco BRL catologno. 18324-020) mediated gene transfer.

Example 5 Isolation of Recombinant FPRL1

FPRL1 is expressed as a chimeric protein with one or more additionalpolypeptide domains added to facilitate protein purification. Suchpurification facilitating domains include, but are not limited to, metalchelating peptides such as histidine-tryptophan modules that allowpurification on immobilized metals [Appa Rao, 1997] and the domainutilized in the FLAGS extension/affinity purification system (ImmunexCorp., Seattle, Wash.). The inclusion of a cleavable linker sequencesuch as Factor Xa or enterokinase (Invitrogen, Groningen, TheNetherlands) between the purification domain and the FPRL1 sequence isuseful to facilitate expression of FPRL1.

Example 6 Testing of Chimeric GPCRs

Functional chimeric GPCRs are constructed by combining the extracellularreceptive sequences of a new isoform with the transmembrane andintracellular segments of a known isoform for test purposes. Thisconcept was demonstrated by Kobilka et al. (1988), Science240:1310-1316) who created a series of chimeric α2-β2 adrenergicreceptors (AR) by inserting progressively greater amounts of α2-ARtransmembrane sequence into β2-AR. The binding activity of knownagonists changed as the molecule shifted from having more α2 than β₂conformation, and intermediate constructs demonstrated mixedspecificity. The specificity for binding antagonists, however,correlated with the source of the domain VII. The importance of T7Gdomain VII for ligand recognition was also found in chimeras utilizingtwo yeast α-factor receptors and is significant because the yeastreceptors are classified as miscellaneous receptors. Thus, functionalrole of specific domains appears to be preserved throughout the GPCRfamily regardless of category.

In parallel fashion, internal segments or cytoplasmic domains from aparticular isoform are exchanged with the analogous domains of a knownGPCRs and used to identify the structural determinants responsible forcoupling the receptors to trimeric G-proteins. A chimeric receptor inwhich domains V, VI and the intracellular connecting loop from β2-ARwere substituted into α2-AR was shown to bind ligands with α2-ARspecificity, but to stimulate adenylate cyclase in the manner of β2-AR.This demonstrates that for adrenergic-type receptors, G-proteinrecognition is present in domains V and VI and their connecting loop.The opposite situation was predicted and observed for a chimera in whichthe V->VI loop from α1-AR replaced the corresponding domain on β2-AR andthe resulting receptor bound ligands with β2-AR specificity andactivated G-protein-mediated phosphatidylinositol turnover in the α1-ARmanner. Finally, chimeras constructed from muscarinic receptors alsodemonstrated that V->VI loop is the major determinant for specificity ofG-protein activity.

Chimeric or modified GPCRs containing substitutions in the extracellularand transmembrane regions have shown that these portions of the receptordetermine ligand binding specificity. For example, two Serine residuesconserved in domain V of all adrenergic and D catecholainine GPCRs arenecessary for potent agonist activity. These serines are believed toform hydrogen bonds with the catechol moiety of the agonists within theGPCR binding site. Similarly, an Asp residue present in domain III ofall GPCRs which bind biogenic amines is believed to form an ion pairwith the ligand amine group in the GPCR binding site.

Functional, cloned GPCRs are expressed in heterologous expressionsystems and their biological activity assessed. One heterologous systemintroduces genes for a mammalian GPCR and a mammalian G-protein intoyeast cells. The GPCR is shown to have appropriate ligand specificityand affinity and trigger appropriate biological activation (growtharrest and morphological changes) of the yeast cells.

An alternate procedure for testing chimeric receptors is based on theprocedure utilizing the purinergic receptor (P₂u). Function is easilytested in cultured K562 human leukemia cells because these cells lackP₂u receptors. K562 cells are transfected with expression vectorscontaining either normal or chimeric P₂u and loaded with fura-a,fluorescent probe for Ca⁺⁺. Activation of properly assembled andfunctional P₂u receptors with extracellular UTP or ATP mobilizesintracellular Ca⁺⁺ which reacts with fura-a and is measuredspectrofluorometrically.

As with the GPCRs above, chimeric genes are created by combiningsequences for extracellular receptive segments of any new GPCRpolypeptide with the nucleotides for the transmembrane and intracellularsegments of the known P₂u molecule. Bathing the transfected K562 cellsin microwells containing appropriate ligands triggers binding andfluorescent activity defining effectors of the GPCR molecule. Onceligand and function are established, the P₂u system is useful fordefining antagonists or inhibitors which block binding and prevent suchfluorescent reactions.

Example 7 Production of FPRL1 Specific Antibodies

Two approaches are utilized to raise antibodies to FPRL1, and eachapproach is useful for generating either polygonal or monoclonalantibodies. In one approach, denatured protein from reverse phase HPLCseparation is obtained in quantities up to 75 mg. This denatured proteinis used to immunize mice or rabbits using standard protocols; about 100μg are adequate for immunization of a mouse, while up to 1 mg might beused to immunize a rabbit. For identifying mouse hybridomas, thedenatured protein is radioiodinated and used to screen potential murineB-cell hybridomas for those which produce antibody. This procedurerequires only small quantities of protein, such that 20 mg is sufficientfor labeling and screening of several thousand clones.

In the second approach, the amino acid sequence of an appropriate FPRL1domain, as deduced from translation of the cDNA, is analyzed todetermine regions of high antigenicity. Oligopeptides comprisingappropriate hydrophilic regions are synthesized and used in suitableimmunization protocols to raise antibodies. The optimal amino acidsequences for immunization are usually at the C-terminus, the N-terminusand those intervening, hydrophilic regions of the polypeptide which arelikely to be exposed to the external environment when the protein is inits natural conformation.

Typically, selected peptides, about 15 residues in length, aresynthesized using an Applied Biosystems Peptide Synthesizer Model 431Ausing fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH;Sigma, St. Louis, Mo.) by reaction withM-maleimidobenzoyl-N-hydroxysuccinimide ester, MBS. If necessary, acysteine is introduced at the N-terminus of the peptide to permitcoupling to KLH. Rabbits are immunized with the peptide-KLH complex incomplete Freund's adjuvant. The resulting antisera are tested forantipeptide activity by binding the peptide to plastic, blocking with 1%bovine serum albumin, reacting with antisera, washing and reacting withlabeled (radioactive or fluorescent), affinity purified, specific goatanti-rabbit IgG.

Hybridomas are prepared and screened using standard techniques.Hybridomas of interest are detected by screening with labeled FPRL1 toidentify those fusions producing the monoclonal antibody with thedesired specificity. In a typical protocol, wells of plates (FAST;Becton-Dickinson, Palo Alto, Calif.) are coated during incubation withaffinity purified, specific rabbit anti-mouse (or suitable antispecies 1g) antibodies at 10 mg/ml. The coated wells are blocked with 1% bovineserum albumin, (BSA), washed and incubated with supernatants fromhybridomas. After washing the wells are incubated with labeled FPRL1 at1 mg/ml. Supernatants with specific antibodies bind more labeled FPRL1than is detectable in the background. Then clones producing specificantibodies are expanded and subjected to two cycles of cloning atlimiting dilution. Cloned hybridomas are injected into pristane-treatedmice to produce ascites, and monoclonal antibody is purified from mouseascitic fluid by affinity chromatography on Protein A. Monoclonalantibodies with affinities of at least 10⁸ M⁻¹, preferably 10⁹ to 10¹⁰M⁻¹ or stronger, are typically made by standard procedures.

Example 8 Diagnostic Test Using FPRL1 Specific Antibodies

Particular FPRL1 antibodies are useful for investigating signaltransduction and the diagnosis of infectious or hereditary conditionswhich are characterized by differences in the amount or distribution ofFPRL1 or downstream products of an active signaling cascade.

Diagnostic tests for FPRL1 include methods utilizing antibody and alabel to detect FPRL1 in human body fluids, membranes, cells, tissues orextracts of such. The polypeptides and antibodies of the presentinvention are used with or without modification. Frequently, thepolypeptides and antibodies are labeled by joining them, eithercovalently or noncovalently, with a substance which provides for adetectable signal. A wide variety of labels and conjugation techniquesare known and have been reported extensively in both the scientific andpatent literature. Suitable labels include radionuclides, enzymes,substrates, cofactors, inhibitors, fluorescent agents, chemiluminescentagents, chromogenic agents, magnetic particles and the like.

A variety of protocols for measuring soluble or membrane-bound FPRL1,using either polyclonal or monoclonal antibodies specific for theprotein, are known in the art. Examples include enzyme-linkedimmunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescentactivated cell sorting (FACS). A two-site monoclonal-based immunoassayutilizing monoclonal antibodies reactive to two non-interfering epitopeson FPRL1 is preferred, but a competitive binding assay may be employed.

Example 9 Purification of Native FPRL1 Using Specific Antibodies

Native or recombinant FPRL1 is purified by immunoaffinity chromatographyusing antibodies specific for FPRL1. In general, an immunoaffinitycolumn is constructed by covalently coupling the anti-TRH antibody to anactivated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either byprecipitation with ammonium sulfate or by purification on immobilizedProtein A (Pharmacia LKB Biotechnology, Piscataway N.J.). Likewise,monoclonal antibodies are prepared from mouse ascites fluid by ammoniumsulfate precipitation or chromatography on immobilized Protein A.Partially purified immunoglobulin is covalently attached to achromatographic resin such as CnBr-activated Sepharose (Pharmacia LKBBiotechnology). The antibody is coupled to the resin, the resin isblocked, and the derivative resin is washed according to themanufacturer's instructions.

Such immunoaffinity columns are utilized in the purification of FPRL1 bypreparing a fraction from cells containing FPRL1 in a soluble form. Thispreparation is derived by solubilization of whole cells or of asubcellular fraction obtained via differential centrifugation (with orwithout addition of detergent) or by other methods well known in theart. Alternatively, soluble FPRL1 containing a signal sequence issecreted in useful quantity into the medium in which the cells aregrown.

A soluble FPRL1-containing preparation is passed over the immunoaffinitycolumn, and the column is washed under conditions that allow thepreferential absorbance of FPRL1 (e.g., high ionic strength buffers inthe presence of detergent). Then, the column is eluted under conditionsthat disrupt antibody/protein binding (e.g., a buffer of pH 2-3 or ahigh concentration of a chaotrope such as urea or thiocyanate ion), andFPRL1 is collected.

Example 10 Drug Screening

This invention is particularly useful for screening therapeuticcompounds by using FPRL1 or binding fragments thereof in any of avariety of drug screening techniques. As FPRL1 is a G protein coupledreceptor any of the methods commonly used in the art may potentially beused to identify FPRL1 ligands. For example, the activity of a G proteincoupled receptor such as FPRL1 can be measured using any of a variety ofappropriate functional assays in which activation of the receptorresults in an observable change in the level of some second messengersystem, such as adenylate cyclase, guanylylcyclase, calciummobilization, or inositol phospholipid hydrolysis. Alternatively, thepolypeptide or fragment employed in such a test is either free insolution, affixed to a solid support, borne on a cell surface or locatedintracellularly. One method of drug screening utilizes eukaryotic orprokaryotic host cells which are stably transformed with recombinantnucleic acids expressing the polypeptide or fragment. Drugs are screenedagainst such transformed cells in competitive binding assays. Suchcells, either in viable or fixed form, are used for standard bindingassays.

Measured, for example, is the formation of complexes between FPRL1 andthe agent being tested. Alternatively, one examines the diminution incomplex formation between FPRL1 and a ligand caused by the agent beingtested.

Thus, the present invention provides methods of screening for drugcanditates, drugs, or any other agents which affect signal transduction.These methods, well known in the art, comprise contacting such an agentwith FPRL1 polypeptide or a fragment thereof and assaying (i) for thepresence of a complex between the agent and FPRL1 polypeptide orfragment, or (ii) for the presence of a complex between FPRL1polypeptide or fragment and the cell. In such competitive bindingassays, the FPRL1 polypeptide or fragment is typically labeled. Aftersuitable incubation, free FPRL1 polypeptide or fragment is separatedfrom that present in bound form, and the amount of free or uncomplexedlabel is a measure of the ability of the particular agent to bind toFPRL1 or to interfere with the FPRL1-agent complex.

Another technique for drug screening provides high throughput screeningfor compounds having suitable binding affinity to FPRL1 polypeptides.Briefly stated, large numbers of different small peptide test compoundsare synthesized on a solid substrate, such as plastic pins or some othersurface. The peptide test compounds are reacted with FPRL1 polypeptideand washed. Bound FPRL1 polypeptide is then detected by methods wellknown in the art. Purified FPRL1 are also coated directly onto platesfor use in the aforementioned drug screening techniques. In addition,non-neutralizing antibodies are used to capture the peptide andimmobilize it on the solid support.

This invention also contemplates the use of competitive drug screeningassays in which neutralizing antibodies capable of binding FPRL1specifically compete with a test compound for binding to FPRL1polypeptides or fragments thereof. In this manner, the antibodies areused to detect the presence of any peptide which shares one or moreantigenic determinants with FPRL 1.

Example 11 Rational Drug Design

The goal of rational drug design is to produce structural analogs ofbiologically active polypeptides of interest or of small molecules withwhich they interact, agonists, antagonists, or inhibitors. Any of theseexamples are used to fashion drugs which are more active or stable formsof the polypeptide or which enhance or interfere with the function of apolypeptide in vivo.

In one approach, the three-dimensional structure of a protein ofinterest, or of a protein-inhibitor complex, is determined by x-raycrystallography, by computer modeling or, most typically, by acombination of the two approaches. Both the shape and charges of thepolypeptide must be ascertained to elucidate the structure and todetermine active site(s) of the molecule. Less often, useful informationregarding the structure of a polypeptide is gained by modeling based onthe structure of homologous proteins. In both cases, relevant structuralinformation is used to design efficient inhibitors. Useful examples ofrational drug design include molecules which have improved activity orstability or which act as inhibitors, agonists, or antagonists of nativepeptides.

It is also possible to isolate a target-specific antibody, selected byfunctional assay, as described above, and then to solve its crystalstructure. This approach, in principle, yields a pharmacore upon whichsubsequent drug design is based. It is possible to bypass proteincrystallography altogether by generating anti-idiotypic antibodies(anti-ids) to a functional, pharmacologically active antibody. As amirror image of a mirror image, the binding site of the anti-ids isexpected to be an analog of the original receptor. The anti-id is thenused to identify and isolate peptides from banks of chemically orbiologically produced peptides. The isolated peptides then act as thepharmacore.

By virtue of the present invention, sufficient amount of polypeptide aremade available to perform such analytical studies as X-raycrystallography. In addition, knowledge of the FPRL1 amino acid sequenceprovided herein provides guidance to those employing computer modelingtechniques in place of or in addition to x-ray crystallography.

Example 12 Identification of Other Members of the Signal TransductionComplex

The inventive purified FPRL1 is a research tool for identification,characterization and purification of interacting G or other signaltransduction pathway proteins. Radioactive labels are incorporated intoa selected FPRL1 domain by various methods known in the art and used invitro to capture interacting molecules. A preferred method involveslabeling the primary amino groups in FPRL1 with ¹²⁵I Bolton-Hunterreagent. This reagent has been used to label various molecules withoutconcomitant loss of biological activity.

Labeled FPRL1 is useful as a reagent for the purification of moleculeswith which it interacts. In one embodiment of affinity purification,membrane-bound FPRL1 is covalently coupled to a chromatography column.Cell-free extract derived from synovial cells or putative target cellsis passed over the column, and molecules with appropriate affinity bindto FPRL1. FPRL1-complex is recovered from the column, and theFPRL1-binding ligand disassociated and subjected to N-terminal proteinsequencing. The amino acid sequence information is then used to identifythe captured molecule or to design degenerate oligonucleotide probes forcloning the relevant gene from an appropriate cDNA library.

In an alternate method, antibodies are raised against FPRL1,specifically monoclonal antibodies. The monoclonal antibodies arescreened to identify those which inhibit the binding of labeled FPRL1.These monoclonal antibodies are then used therapeutically.

Example 13 Use and Administration of Antibodies, Inhibitors, orAntagonists

Antibodies, inhibitors, or antagonists of FPRL1 or other treatments andcompunds that are limiters of signal transduction (LSTs), providedifferent effects when administered therapeutically. LSTs are formulatedin a nontoxic, inert, pharmaceutically acceptable aqueous carrier mediumpreferably at a pH of about 5 to 8, more preferably 6 to 8, although pHmay vary according to the characteristics of the antibody, inhibitor, orantagonist being formulated and the condition to be treated.Characteristics of LSTs include solubility of the molecule, itshalf-life and antigenicity/immunogenicity. These and othercharacteristics aid in defining an effective carrier. Native humanproteins are preferred as LSTs, but organic or synthetic moleculesresulting from drug screens are equally effective in particularsituations.

LSTs are delivered by known routes of administration including but notlimited to topical creams and gels; transmucosal spray and aerosol;transdermal patch and bandage; injectable, intravenous and lavageformulations; and orally administered liquids and pills particularlyformulated to resist stomach acid and enzymes. The particularformulation, exact dosage, and route of administration is determined bythe attending physician and varies according to each specific situation.

Such determinations are made by considering multiple variables such asthe condition to be treated, the LST to be administered, and thepharmacokinetic profile of a particular LST. Additional factors whichare taken into account include severity of the disease state, patient'sage, weight, gender and diet, time and frequency of LST administration,possible combination with other drugs, reaction sensitivities, andtolerance/response to therapy. Long acting LST formulations might beadministered every 3 to 4 days, every week, or once every two weeksdepending on half-life and clearance rate of the particular LST.

Normal dosage amounts vary from 0.1 to 10⁵ μg, up to a total dose ofabout 1 g, depending upon the route of administration. Guidance as toparticular dosages and methods of delivery is provided in theliterature; see U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. Thoseskilled in the art employ different formulations for different LSTs.Administration to cells such as nerve cells necessitates delivery in amanner different from that to other cells such as vascular endothelialcells.

It is contemplated that abnormal signal transduction, trauma, ordiseases which trigger FPRL1 activity are treatable with LSTs. Theseconditions or diseases are specifically diagnosed by the tests discussedabove, and such testing should be performed in suspected cases of viral,bacterial or fungal infections, allergic responses, mechanical injuryassociated with trauma, hereditary diseases, lymphoma or carcinoma, orother conditions which activate the genes of lymphoid or neuronaltissues.

Example 14 Production of Non-Human Transgenic Animals

Animal model systems which elucidate the physiological and behavioralroles of the FPRL1 are produced by creating nonhuman transgenic animalsin which the activity of the FPRL1 is either increased or decreased, orthe amino acid sequence of the expressed FPRL1 is altered, by a varietyof techniques. Examples of these techniques include, but are not limitedto: 1) Insertion of normal or mutant versions of DNA encoding a FPRL1,by microinjection, electroporation, retroviral transfection or othermeans well known to those skilled in the art, into appropriatelyfertilized embryos in order to produce a transgenic animal or 2)homologous recombination of mutant or normal, human or animal versionsof these genes with the native gene locus in transgenic animals to alterthe regulation of expression or the structure of these FPRL1 sequences.The technique of homologous recombination is well known in the art. Itreplaces the native gene with the inserted gene and hence is useful forproducing an animal that cannot express native FPRL1s but does express,for example, an inserted mutant FPRL1, which has replaced the nativeFPRL1 in the animal's genome by recombination, resulting inunderexpression of the transporter. Microinjection adds genes to thegenome, but does not remove them, and the technique is useful forproducing an animal which expresses its own and added FPRL1, resultingin overexpression of the FPRL1.

One means available for producing a transgenic animal, with a mouse asan example, is as follows: Female mice are mated, and the resultingfertilized eggs are dissected out of their oviducts. The eggs are storedin an appropriate medium such as cesiumchloride M2 medium. DNA or cDNAencoding FPRL1 is purified from a vector by methods well known to theone skilled in the art. Inducible promoters may be fused with the codingregion of the DNA to provide an experimental means to regulateexpression of the transgene. Alternatively or in addition, tissuespecific regulatory elements may be fused with the coding region topermit tissue-specific expression of the transgene. The DNA, in anappropriately buffered solution, is put into a microinjection needle(which may be made from capillary tubing using a piper puller) and theegg to be injected is put in a depression slide. The needle is insertedinto the pronucleus of the egg, and the DNA solution is injected. Theinjected egg is then transferred into the oviduct of a pseudopregnantmouse which is a mouse stimulated by the appropriate hormones in orderto maintain false pregnancy, where it proceeds to the uterus, implants,and develops to term. As noted above, micro-injection is not the onlymethod for inserting DNA into the egg but is used here only forexemplary purposes.

REFERENCES

-   U.S. Pat. No. 4,522,811-   U.S. Pat. No. 5,283,317-   U.S. Pat. No. 5,565,332-   WO 84/03564-   WO 92/01810-   WO 93/03151-   WO 94/13804-   WO 01/04297-   WO 01/77172-   Durstin M. et al., Biochem Biophys Res Commun, 1994 May 30;    201(1):174-9-   Murphy P. M. et al., J Biol Chem 1992 Apr. 15; 267(11):7637-43-   Appa Rao et al., 1997, Protein Expr Purif November, 11(2): 201-8-   Barnes, 2000, Chest, 117:10S14S-   Botstein et al., 1980, Am J Hum Genet. 32: 314-31-   Colbere-Garapin et al., 1981, J. Mol, Biol. 150, 1-14-   Engelhard et al., 1994, Proc. Nat. Acad. Sci. 91, 3224-3227-   Gergen and Weiss, 1992, Am Rev Respir Dis 146:823-824-   Gibson et al., 1996, Genome Research 6: 995-1001-   Haseloff et al., 1988, Nature 334, 585-591-   Heid et al., 1996, Genome Research 6: 986-994-   Holland et al., 1991, PNAS 88: 7276-7280-   Iwabuchi et al., 1993, Oncogene 8, 1693-1696-   Jeffreys et al., 1985, Nature 316: 76-9-   Johnson et al., 1989, Endoc. Rev. 10, 317-331-   Kellogg et al., 1990, Anal. Biochem. 189:202-208-   Lam, 1997, Anticancer Drug Res. 12(3):145-67-   Lefkowitz, 1991, Nature 351, 353-354-   Livak et al., 1995, PCR Methods and Applications 357-362-   Logan, Shenk, 1984, Proc. Natl. Acad. Sci. 81, 3655-3659-   Lowy et al., 1980, Cell 22, 817-23-   Maddox et al., 1983, J. Exp. Med. 158, 1211-1216-   McConnell et al., 1992, Science 257, 1906-1912-   Murray, 1992, supra-   Nicholls et al., 1993, J. Immunol. Meth. 165, 81-91-   Piatak et al., 1993, BioTechniques 14:70-81-   Piatak et al., 1993, Science 259:1749-1754-   Porath et al., 1992, Prot. Exp. Purif 3, 263-281-   Roberge et al., 1995, Science 269, 202-204-   Sjolander, Urbaniczky, 1991, Anal. Chem. 63, 2338-2345-   Szabo et al., 1995, Curr. Opin. Struct. Biol. 5, 699-705-   Thomas, 1980, Proc. Nat. Acad. Sci., 77:5201-5205-   Uhlmann et al., 1987, Tetrahedrion. Lett. 215, 3539-3542-   Weber et al., 1990, Genomics 7: 524-30-   Wigler et al., 1977, Cell 11, 223-32-   Wigler et al., 1980, Proc. Natl. Acad. Sci. 77, 3567-70

1. A method of screening for therapeutic agents useful in the treatmentof a disease selected from hematological diseases, cardiovasculardiseases, disorders of the peripheral and central nervous system,respiratory diseases, COPD, asthma, genito-urological disorders andinflammation diseases in a mammal comprising the steps of i) contactinga test compound with a FPRL1 polypeptide, ii) detecting binding of saidtest compound to said FPRL1 polypeptide.
 2. A method of screening fortherapeutic agents useful in the treatment of a disease selected fromhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases, COPD,asthma, genito-urological disorders and inflammation diseases in amammal comprising the steps of i) determining the activity of a FPRL1polypeptide at a certain concentration of a test compound or in theabsence of said test compound, ii) determining the activity of saidpolypeptide at a different concentration of said test compound.
 3. Amethod of screening for therapeutic agents useful in the treatment of adisease selected from hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases, COPD, asthma, genito-urological disorders and inflammationdiseases in a mammal comprising the steps of i) determining the activityof a FPRL1 polypeptide at a certain concentration of a test compound,ii) determining the activity of a FPRL1 polypeptide at the presence of acompound known to be a regulator of a FPRL1 polypeptide.
 4. The methodof claim 1, wherein the step of contacting is in or at the surface of acell.
 5. The method of claim 1, wherein the cell is in vitro.
 6. Themethod of claim 1, wherein the step of contacting is in a cellfreesystem.
 7. The method of claim 1, wherein the polypeptide is coupled toa detectable label.
 8. The method of claim 1, wherein the compound iscoupled to a detectable label.
 9. The method of claim 1, wherein thetest compound displaces a ligand which is first bound to thepolypeptide.
 10. The method of claim 1, wherein the polypeptide isattached to a solid support.
 11. The method of claim 1, wherein thecompound is attached to a solid support.
 12. A method of screening fortherapeutic agents useful in the treatment of a disease selected fromhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases, COPD,asthma, genito-urological disorders and inflammation diseases in amammal comprising the steps of i) contacting a test compound with aFPRL1 polynucleotide, ii) detect binding of said test compound to saidFPRL1 polynucleotide.
 13. The method of claim 12 wherein the nucleicacid molecule is RNA.
 14. The method of claim 12 wherein the contactingstep is in or at the surface of a cell.
 15. The method of claim 12wherein the contacting step is in a cell-free system.
 16. The method ofclaim 12 wherein polynucleotide is coupled to a detectable label. 17.The method of claim 12 wherein the test compound is coupled to adetectable label.
 18. A method of diagnosing a disease selected fromhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases, COPD,asthma, genitourological disorders and inflammation diseases in a mammalcomprising the steps of i) determining the amount of a FPRL1polynucleotide in a sample taken from said mammal, ii) determining theamount of FPRL1 polynucleotide in healthy and/or diseased mammals.
 19. Apharmaceutical composition for the treatment of a disease selected fromhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases, COPD,asthma, genito-urological disorders and inflammation diseases in amammal comprising a therapeutic agent which binds to a FPRL1polypeptide.
 20. A pharmaceutical composition for the treatment of adisease selected from hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases, COPD, asthma, genito-urological disorders and inflammationdiseases in a mammal comprising a therapeutic agent which regulates theactivity of a FPRL1 polypeptide.
 21. A pharmaceutical composition forthe treatment of a disease selected from hematological diseases,cardiovascular diseases, disorders of the peripheral and central nervoussystem, respiratory diseases, COPD, asthma, genito-urological disordersand inflammation diseases in a mammal comprising a therapeutic agentwhich regulates the activity of a FPRL1 polypeptide, wherein saidtherapeutic agent is i) a small molecule, ii) an RNA molecule, iii) anantisense oligonucleotide, iv) a polypeptide, v) an antibody, or vi) aribozyme.
 22. A pharmaceutical composition for the treatment of adisease selected from hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases, COPD, asthma, genito-urological disorders and inflammationdiseases in a mammal comprising a FPRL1 polynucleotide.
 23. Apharmaceutical composition for the treatment of a disease selected fromhematological diseases, cardiovascular diseases, disorders of theperipheral and central nervous system, respiratory diseases, COPD,asthma, genito-urological disorders and inflammation diseases in amammal comprising a FPRL1 polypeptide.
 24. A method for the treatment ofa disease selected from hematological diseases, cardiovascular diseases,disorders of the peripheral and central nervous system, respiratorydiseases, COPD, asthma, genitourological disorders and inflammationdiseases in a mammal comprising administering to a mammal an effectiveamount of a regulator of FPRL1.
 25. Method for the preparation of apharmaceutical composition useful for the treatment of a diseaseselected from hematological diseases, cardiovascular diseases, disordersof the peripheral and central nervous system, respiratory diseases,COPD, asthma, genito-urological disorders and inflammation diseases in amammal comprising the steps of i) identifying a regulator of FPRL1, ii)determining whether said regulator ameliorates the symptoms of a diseaseselected from hematological diseases, cardiovascular diseases, disordersof the peripheral and central nervous system, respiratory diseases,COPD, asthma, genito-urological disorders and inflammation diseases in amammal; and iii) combining of said regulator with an acceptablepharmaceutical carrier.
 26. A method for the regulation of FPRL1activity in a mammal having a disease selected from hematologicaldiseases, cardiovascular diseases, disorders of the peripheral andcentral nervous system, respiratory diseases, COPD, asthma,genito-urological disorders and inflammation diseases comprisingadministering to a mammal an effective amount of a regulator of FPRL1.